```
=> d his nofile

     (FILE 'REGISTRY' ENTERED AT 12:42:14 ON 20 AUG 2007)
               DEL HIS Y
               E THIOURACIL/CN
L1             1 SEA ABB=ON  PLU=ON  THIOURACIL/CN
L2               STR 141-90-2
L3            70 SEA FAM FUL L2


     FILE 'CAPLUS' ENTERED AT 12:43:33 ON 20 AUG 2007
L4          2397 SEA ABB=ON  PLU=ON  L3
L5         17206 SEA ABB=ON  PLU=ON  EAR/OBI OR HEARING/OBI
L6          3295 SEA ABB=ON  PLU=ON  OTO?/OBI
L7         18670 SEA ABB=ON  PLU=ON  L5 OR L6
L8             2 SEA ABB=ON  PLU=ON  L7 AND L4
               D SCAN
L9         25449 SEA ABB=ON  PLU=ON  EAR/AB OR (HEAR OR HEARING)/AB
L10            4 SEA ABB=ON  PLU=ON  L9 AND L4
               E EAR DISEASE/CT
               E E12+ALL
L11         5888 SEA ABB=ON  PLU=ON  (DEAF? OR TINNITUS)/BI
L12            1 SEA ABB=ON  PLU=ON  L4 AND L11
L13         2236 SEA ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR DYSACUSIS OR
               HYPERACUSIS OR OTITIS)/BI
L14            1 SEA ABB=ON  PLU=ON  L4 AND L13
               D SCAN
L15            6 SEA ABB=ON  PLU=ON  L14 OR L12 OR L10 OR L8

     FILE 'MEDLINE' ENTERED AT 12:51:06 ON 20 AUG 2007
               E EAR DISEASES/CT
               E E3+ALL
L16        99503 SEA ABB=ON  PLU=ON  EAR DISEASES+NT/CT
L17       191347 SEA ABB=ON  PLU=ON  L16 OR EAR OR HEARING OR OTO?
L18         1675 SEA ABB=ON  PLU=ON  L1
               D TRIAL
               E THIOURACIL/CT
               E E3+ALL
L19         1675 SEA ABB=ON  PLU=ON  L18 OR THIOURACIL/CT
L20            6 SEA ABB=ON  PLU=ON  L19 AND L17
               D TRIAL 1
               E AMIONGLYCOSIDE ANTIBIOTIC/CT
               E ANTIBIOTICS/CT
               E E3+AKK
               E E3+ALL
               E E2+ALL
               E AMINOGLYCOSIDES/CT
               E E3+ALL
L21       102336 SEA ABB=ON  PLU=ON  AMINOGLYCOSIDES+NT/CT
L22           17 SEA ABB=ON  PLU=ON  L21 AND L19
L23         3645 SEA ABB=ON  PLU=ON  OTOPROTECT? OR OTOTOX?
L24            0 SEA ABB=ON  PLU=ON  L23 AND L19
L25       114262 SEA ABB=ON  PLU=ON  ANTINEOPLASTIC AGENTS/CT
L26            0 SEA ABB=ON  PLU=ON  ANTINEOPLASTIC AGENTS+NT/DCT
L27       682114 SEA ABB=ON  PLU=ON  ANTINEOPLASTIC AGENTS+NT/CT
L28           88 SEA ABB=ON  PLU=ON  L19 AND L27
L29            0 SEA ABB=ON  PLU=ON  L28 AND L16
L30            0 SEA ABB=ON  PLU=ON  L22 AND L16
L31            9 SEA ABB=ON  PLU=ON  ZEPP C?/AU
```

```
L32          10 SEA ABB=ON  PLU=ON  HEEFNER D?/AU
L33         884 SEA ABB=ON  PLU=ON  RUBIN P?/AU
L34         230 SEA ABB=ON  PLU=ON  CURRIE M?/AU
L35        1131 SEA ABB=ON  PLU=ON  (L31 OR L32 OR L33 OR L34)
L36           0 SEA ABB=ON  PLU=ON  L35 AND L19
L37           0 SEA ABB=ON  PLU=ON  L35 AND L16
L38           8 SEA ABB=ON  PLU=ON  L35 AND L5


     FILE 'CAPLUS' ENTERED AT 13:06:41 ON 20 AUG 2007
L39          67 SEA ABB=ON  PLU=ON  ZEPP C?/AU
L40          40 SEA ABB=ON  PLU=ON  HEEFNER D?/AU
L41         612 SEA ABB=ON  PLU=ON  RUBIN P?/AU
L42         353 SEA ABB=ON  PLU=ON  CURRIE M?/AU
L43        1049 SEA ABB=ON  PLU=ON  (L39 OR L40 OR L41 OR L42)
L44           1 SEA ABB=ON  PLU=ON  L43 AND L4
L45       39597 SEA ABB=ON  PLU=ON  L11 OR L13 OR  L9 OR L6 OR L5
L46           6 SEA ABB=ON  PLU=ON  L43 AND L45
L47           5 SEA ABB=ON  PLU=ON  L46 NOT L44
L48           6 SEA ABB=ON  PLU=ON  L44 OR L15

     FILE 'BIOSIS' ENTERED AT 13:10:17 ON 20 AUG 2007
L49        4297 SEA ABB=ON  PLU=ON  L1 OR THIOURACIL OR THIO URACIL
L50       36512 SEA ABB=ON  PLU=ON  HEAR OR HEARING
L51        2614 SEA ABB=ON  PLU=ON  OTOPRO? OR OTOTOX?
L52       76948 SEA ABB=ON  PLU=ON  EAR
L53           4 SEA ABB=ON  PLU=ON  L49 AND L50
L54           0 SEA ABB=ON  PLU=ON  L49 AND L51
L55          10 SEA ABB=ON  PLU=ON  L49 AND L52
                D SCAN TI L53
                D SCAN TI L55
L56          13 SEA ABB=ON  PLU=ON  L55 OR L53
L57          17 SEA ABB=ON  PLU=ON  ZEPP C?/AU
L58          32 SEA ABB=ON  PLU=ON  HEEFNER D?/AU
L59         928 SEA ABB=ON  PLU=ON  RUBIN P?/AU
L60         355 SEA ABB=ON  PLU=ON  CURRIE M?/AU
L61        1324 SEA ABB=ON  PLU=ON  (L57 OR L58 OR L59 OR L60)
L62           1 SEA ABB=ON  PLU=ON  L61 AND (L50 OR L51 )
L63           0 SEA ABB=ON  PLU=ON  L61 AND L49


     FILE 'EMBASE' ENTERED AT 13:19:52 ON 20 AUG 2007
L64         560 SEA ABB=ON  PLU=ON  L3
                E THIOURACIL/CT
                E E3+ALL
L65        1197 SEA ABB=ON  PLU=ON  THIOURACIL/CT OR L64 OR THIOURACIL OR
                MERCAPTOURACIL
L66      140880 SEA ABB=ON  PLU=ON  HEAR OR HEARING OR EAR OR OTO? OR OTITIS
L67           5 SEA ABB=ON  PLU=ON  L65 AND L66
L68       20902 SEA ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR DYSACUSIS OR
                HYPERACUSIS OR OTITIS)/BI
L69           0 SEA ABB=ON  PLU=ON  L68 AND L64
L70          62 SEA ABB=ON  PLU=ON  OTOPROTECT?
L71           0 SEA ABB=ON  PLU=ON  L70 AND ?URACIL?

     FILE 'BIOSIS' ENTERED AT 13:23:53 ON 20 AUG 2007
L72       12069 SEA ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR DYSACUSIS OR
                HYPERACUSIS OR OTITIS)/BI
L73           1 SEA ABB=ON  PLU=ON  L72 AND L49
L74           5 SEA ABB=ON  PLU=ON  L73 OR L53
```

```
     FILE 'EMBASE' ENTERED AT 13:25:32 ON 20 AUG 2007
L75            5 SEA ABB=ON  PLU=ON  ZEPP C?/AU
L76           10 SEA ABB=ON  PLU=ON  HEEFNER D?/AU
L77          756 SEA ABB=ON  PLU=ON  RUBIN P?/AU
L78          206 SEA ABB=ON  PLU=ON  CURRIE M?/AU
L79          975 SEA ABB=ON  PLU=ON  (L75 OR L76 OR L77 OR L78)
L80            0 SEA ABB=ON  PLU=ON  L79 AND L65
L81           12 SEA ABB=ON  PLU=ON  L66 AND L79

     FILE 'WPIX' ENTERED AT 13:27:28 ON 20 AUG 2007
L82          321 SEA ABB=ON  PLU=ON  THIOURACIL OR MERCAPTOURACIL OR (MERCAPTO
                 OR THIO) (2A) URACIL
L83          197 SEA ABB=ON  PLU=ON  DERACIL OR ANTAGOTHYROIL OR NOBILEN OR NSC

L84            5 SEA ABB=ON  PLU=ON  HYDROXY (2W) (MERCAPTOPYRIMIDINE OR
                 PYRIMIDINETHIOL OR MERCAPTOPYRIMIDINE)
L85          522 SEA ABB=ON  PLU=ON  (L82 OR L83 OR L84)
L86        40192 SEA ABB=ON  PLU=ON  EAR OR HEAR OR HEARING OR OTO? OR OTITIS
                 OR TINNITUS
L87         1456 SEA ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR DYSACUSIS OR
                 HYPERACUSIS OR OTITIS)/BI
L88        40202 SEA ABB=ON  PLU=ON  L86 OR L87
L89            2 SEA ABB=ON  PLU=ON  L88 AND L85
L90           57 SEA ABB=ON  PLU=ON  ZEPP C?/AU
L91           27 SEA ABB=ON  PLU=ON  HEEFNER D?/AU
L92           50 SEA ABB=ON  PLU=ON  RUBIN P?/AU
L93          104 SEA ABB=ON  PLU=ON  CURRIE M?/AU
L94          217 SEA ABB=ON  PLU=ON  (L90 OR L91 OR L92 OR L93)
L95            0 SEA ABB=ON  PLU=ON  L94 AND L85 L
L96            8 SEA ABB=ON  PLU=ON  L94 AND L88

     FILE 'CAPLUS, MEDLINE, BIOSIS, EMBASE, WPIX' ENTERED AT 13:35:26 ON 20
     AUG 2007
L97           21 DUP REM L47 L20 L74 L67 L89 (2 DUPLICATES REMOVED)
                    ANSWERS '1-5' FROM FILE CAPLUS
                    ANSWERS '6-11' FROM FILE MEDLINE
                    ANSWERS '12-16' FROM FILE BIOSIS
                    ANSWERS '17-19' FROM FILE EMBASE
                    ANSWERS '20-21' FROM FILE WPIX
L98           27 DUP REM L48 L38 L62 L81 L96 (8 DUPLICATES REMOVED)
                    ANSWERS '1-6' FROM FILE CAPLUS
                    ANSWERS '7-14' FROM FILE MEDLINE
                    ANSWERS '15-20' FROM FILE EMBASE
                    ANSWERS '21-27' FROM FILE WPIX

     FILE 'CAPLUS, MEDLINE, EMBASE' ENTERED AT 13:36:15 ON 20 AUG 2007
L99        22341 SEA ABB=ON  PLU=ON  PYRIMIDIN? (3A) DERIV?
L100      284499 SEA ABB=ON  PLU=ON  EAR OR HEAR OR HEARING OR TINNITIS OR
                 OTITIS OR L13
L101          24 SEA ABB=ON  PLU=ON  L99 AND L100
L102          23 DUP REM L101 (1 DUPLICATE REMOVED)
                    ANSWERS '1-9' FROM FILE CAPLUS
                    ANSWERS '10-11' FROM FILE MEDLINE
                    ANSWERS '12-23' FROM FILE EMBASE
L103      891759 SEA ABB=ON  PLU=ON  OTOPROTEC? OR PROTECT?
L104           0 SEA ABB=ON  PLU=ON  L102 AND L103
L105       54949 SEA ABB=ON  PLU=ON  HEARING (2A) LOSS
L106           2 SEA ABB=ON  PLU=ON  L105 AND L99
                 D SCAN
```

```
L107       17784 SEA ABB=ON  PLU=ON  PYRIMIDINE## (3A) DERIV?
L108           2 SEA ABB=ON  PLU=ON  L105 AND L107


=> fil reg
FILE 'REGISTRY' ENTERED AT 13:41:33 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 AUG 2007  HIGHEST RN 944998-48-5
DICTIONARY FILE UPDATES:  19 AUG 2007  HIGHEST RN 944998-48-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l3
L2              STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L3            70 SEA FILE=REGISTRY FAM FUL L2

100.0% PROCESSED     479 ITERATIONS                    70 ANSWERS
SEARCH TIME: 00.00.01


=> _
```

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 13:41:42 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   19 AUG 2007  HIGHEST RN 944998-48-5
DICTIONARY FILE UPDATES:  19 AUG 2007  HIGHEST RN 944998-48-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que stat l3
L2               STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   8

STEREO ATTRIBUTES: NONE
L3           70 SEA FILE=REGISTRY FAM FUL L2

100.0% PROCESSED     479 ITERATIONS                          70 ANSWERS
SEARCH TIME: 00.00.01


=> fil caplus medline biosis embase wpix
FILE 'CAPLUS' ENTERED AT 13:41:55 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

```
FILE 'MEDLINE' ENTERED AT 13:41:55 ON 20 AUG 2007

FILE 'BIOSIS' ENTERED AT 13:41:55 ON 20 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:41:55 ON 20 AUG 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'WPIX' ENTERED AT 13:41:55 ON 20 AUG 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

=>

=> d que nos l97
L1             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  THIOURACIL/CN
L2               STR
L3            70 SEA FILE=REGISTRY FAM FUL L2
L4          2397 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3
L5         17206 SEA FILE=CAPLUS ABB=ON  PLU=ON  EAR/OBI OR HEARING/OBI
L6          3295 SEA FILE=CAPLUS ABB=ON  PLU=ON  OTO?/OBI
L9         25449 SEA FILE=CAPLUS ABB=ON  PLU=ON  EAR/AB OR (HEAR OR HEARING)/AB

L11         5888 SEA FILE=CAPLUS ABB=ON  PLU=ON  (DEAF? OR TINNITUS)/BI
L13         2236 SEA FILE=CAPLUS ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR
                 DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
L16        99503 SEA FILE=MEDLINE ABB=ON  PLU=ON  EAR DISEASES+NT/CT
L17       191347 SEA FILE=MEDLINE ABB=ON  PLU=ON  L16 OR EAR OR HEARING OR OTO?

L18         1675 SEA FILE=MEDLINE ABB=ON  PLU=ON  L1
L19         1675 SEA FILE=MEDLINE ABB=ON  PLU=ON  L18 OR THIOURACIL/CT
L20            6 SEA FILE=MEDLINE ABB=ON  PLU=ON  L19 AND L17
L39           67 SEA FILE=CAPLUS ABB=ON  PLU=ON  ZEPP C?/AU
L40           40 SEA FILE=CAPLUS ABB=ON  PLU=ON  HEEFNER D?/AU
L41          612 SEA FILE=CAPLUS ABB=ON  PLU=ON  RUBIN P?/AU
L42          353 SEA FILE=CAPLUS ABB=ON  PLU=ON  CURRIE M?/AU
L43         1049 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L39 OR L40 OR L41 OR L42)
L44            1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L43 AND L4
L45        39597 SEA FILE=CAPLUS ABB=ON  PLU=ON  L11 OR L13 OR L9 OR L6 OR L5
L46            6 SEA FILE=CAPLUS ABB=ON  PLU=ON  L43 AND L45
L47            5 SEA FILE=CAPLUS ABB=ON  PLU=ON  L46 NOT L44
L49         4297 SEA FILE=BIOSIS ABB=ON  PLU=ON  L1 OR THIOURACIL OR THIO
                 URACIL
L50        36512 SEA FILE=BIOSIS ABB=ON  PLU=ON  HEAR OR HEARING
L53            4 SEA FILE=BIOSIS ABB=ON  PLU=ON  L49 AND L50
L64          560 SEA FILE=EMBASE ABB=ON  PLU=ON  L3
L65         1197 SEA FILE=EMBASE ABB=ON  PLU=ON  THIOURACIL/CT OR L64 OR
                 THIOURACIL OR MERCAPTOURACIL
L66       140880 SEA FILE=EMBASE ABB=ON  PLU=ON  HEAR OR HEARING OR EAR OR OTO?
                 OR OTITIS
L67            5 SEA FILE=EMBASE ABB=ON  PLU=ON  L65 AND L66
L72        12069 SEA FILE=BIOSIS ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR
                 DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
L73            1 SEA FILE=BIOSIS ABB=ON  PLU=ON  L72 AND L49
L74            5 SEA FILE=BIOSIS ABB=ON  PLU=ON  L73 OR L53
L82          321 SEA FILE=WPIX ABB=ON  PLU=ON  THIOURACIL OR MERCAPTOURACIL OR
                 (MERCAPTO OR THIO) (2A) URACIL
L83          197 SEA FILE=WPIX ABB=ON  PLU=ON  DERACIL OR ANTAGOTHYROIL OR
                 NOBILEN OR NSC
L84            5 SEA FILE=WPIX ABB=ON  PLU=ON  HYDROXY (2W) (MERCAPTOPYRIMIDINE
                 OR PYRIMIDINETHIOL OR MERCAPTOPYRIMIDINE)
```

```
L85          522 SEA FILE=WPIX ABB=ON  PLU=ON  (L82 OR L83 OR L84)
L86        40192 SEA FILE=WPIX ABB=ON  PLU=ON  EAR OR HEAR OR HEARING OR OTO?
                 OR OTITIS OR TINNITUS
L87         1456 SEA FILE=WPIX ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR
                 DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
L88        40202 SEA FILE=WPIX ABB=ON  PLU=ON  L86 OR L87
L89            2 SEA FILE=WPIX ABB=ON  PLU=ON  L88 AND L85
L97           21 DUP REM L47 L20 L74 L67 L89 (2 DUPLICATES REMOVED)


=> d que nos l98
L2                STR
L3             70 SEA FILE=REGISTRY FAM FUL L2
L4           2397 SEA FILE=CAPLUS ABB=ON  PLU=ON  L3
L5          17206 SEA FILE=CAPLUS ABB=ON  PLU=ON  EAR/OBI OR HEARING/OBI
L6           3295 SEA FILE=CAPLUS ABB=ON  PLU=ON  OTO?/OBI
L7          18670 SEA FILE=CAPLUS ABB=ON  PLU=ON  L5 OR L6
L8              2 SEA FILE=CAPLUS ABB=ON  PLU=ON  L7 AND L4
L9          25449 SEA FILE=CAPLUS ABB=ON  PLU=ON  EAR/AB OR (HEAR OR HEARING)/AB

L10             4 SEA FILE=CAPLUS ABB=ON  PLU=ON  L9 AND L4
L11          5888 SEA FILE=CAPLUS ABB=ON  PLU=ON  (DEAF? OR TINNITUS)/BI
L12             1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L4 AND L11
L13          2236 SEA FILE=CAPLUS ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR
                 DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
L14             1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L4 AND L13
L15             6 SEA FILE=CAPLUS ABB=ON  PLU=ON  L14 OR L12 OR L10 OR L8
L31             9 SEA FILE=MEDLINE ABB=ON  PLU=ON  ZEPP C?/AU
L32            10 SEA FILE=MEDLINE ABB=ON  PLU=ON  HEEFNER D?/AU
L33           884 SEA FILE=MEDLINE ABB=ON  PLU=ON  RUBIN P?/AU
L34           230 SEA FILE=MEDLINE ABB=ON  PLU=ON  CURRIE M?/AU
L35          1131 SEA FILE=MEDLINE ABB=ON  PLU=ON  (L31 OR L32 OR L33 OR L34)
L38             8 SEA FILE=MEDLINE ABB=ON  PLU=ON  L35 AND L5
L39            67 SEA FILE=CAPLUS ABB=ON  PLU=ON  ZEPP C?/AU
L40            40 SEA FILE=CAPLUS ABB=ON  PLU=ON  HEEFNER D?/AU
L41           612 SEA FILE=CAPLUS ABB=ON  PLU=ON  RUBIN P?/AU
L42           353 SEA FILE=CAPLUS ABB=ON  PLU=ON  CURRIE M?/AU
L43          1049 SEA FILE=CAPLUS ABB=ON  PLU=ON  (L39 OR L40 OR L41 OR L42)
L44             1 SEA FILE=CAPLUS ABB=ON  PLU=ON  L43 AND L4
L48             6 SEA FILE=CAPLUS ABB=ON  PLU=ON  L44 OR L15
L50         36512 SEA FILE=BIOSIS ABB=ON  PLU=ON  HEAR OR HEARING
L51          2614 SEA FILE=BIOSIS ABB=ON  PLU=ON  OTOPRO? OR OTOTOX?
L57            17 SEA FILE=BIOSIS ABB=ON  PLU=ON  ZEPP C?/AU
L58            32 SEA FILE=BIOSIS ABB=ON  PLU=ON  HEEFNER D?/AU
L59           928 SEA FILE=BIOSIS ABB=ON  PLU=ON  RUBIN P?/AU
L60           355 SEA FILE=BIOSIS ABB=ON  PLU=ON  CURRIE M?/AU
L61          1324 SEA FILE=BIOSIS ABB=ON  PLU=ON  (L57 OR L58 OR L59 OR L60)
L62             1 SEA FILE=BIOSIS ABB=ON  PLU=ON  L61 AND (L50 OR L51 )
L66        140880 SEA FILE=EMBASE ABB=ON  PLU=ON  HEAR OR HEARING OR EAR OR OTO?
                 OR OTITIS
L75             5 SEA FILE=EMBASE ABB=ON  PLU=ON  ZEPP C?/AU
L76            10 SEA FILE=EMBASE ABB=ON  PLU=ON  HEEFNER D?/AU
L77           756 SEA FILE=EMBASE ABB=ON  PLU=ON  RUBIN P?/AU
L78           206 SEA FILE=EMBASE ABB=ON  PLU=ON  CURRIE M?/AU
L79           975 SEA FILE=EMBASE ABB=ON  PLU=ON  (L75 OR L76 OR L77 OR L78)
L81            12 SEA FILE=EMBASE ABB=ON  PLU=ON  L66 AND L79
L86         40192 SEA FILE=WPIX ABB=ON  PLU=ON  EAR OR HEAR OR HEARING OR OTO?
                 OR OTITIS OR TINNITUS
L87          1456 SEA FILE=WPIX ABB=ON  PLU=ON  (HYPOACUSIS OR PRESBYCUSIS OR
                 DYSACUSIS OR HYPERACUSIS OR OTITIS)/BI
```

```
L88        40202 SEA FILE=WPIX ABB=ON  PLU=ON  L86 OR L87
L90           57 SEA FILE=WPIX ABB=ON  PLU=ON  ZEPP C?/AU
L91           27 SEA FILE=WPIX ABB=ON  PLU=ON  HEEFNER D?/AU
L92           50 SEA FILE=WPIX ABB=ON  PLU=ON  RUBIN P?/AU
L93          104 SEA FILE=WPIX ABB=ON  PLU=ON  CURRIE M?/AU
L94          217 SEA FILE=WPIX ABB=ON  PLU=ON  (L90 OR L91 OR L92 OR L93)
L96            8 SEA FILE=WPIX ABB=ON  PLU=ON  L94 AND L88
L98           27 DUP REM L48 L38 L62 L81 L96 (8 DUPLICATES REMOVED)


=> d .ca hitstr l97 1-5; d ibib ab ct l87 6-21; d ibib l98 1-27

L97  ANSWER 1 OF 21  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2006:1311249  CAPLUS  Full-text
DOCUMENT NUMBER:          146:55519
TITLE:                    Bacterial enterotoxin ST peptide variants that
                          activate the guanylate cyclase C receptor and their
                          use for the treatment of gastrointestinal disorders
INVENTOR(S):              Currie, Mark G.; Mahajan-Miklos, Shalina
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ., 103pp., Cont.-in-part of U.S.
                          Ser. No. 796,719.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   5
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ---------------       ----   --------    --------------------     --------
     US 2006281682          A1    20061214    US 2004-845895           20040514
     US 2004266989          A1    20041230    US 2004-766735           20040128
     US 2005020811          A1    20050127    US 2004-796719           20040309
     US 2006258593          A1    20061116    US 2004-899806           20040727
     AU 2005222387          A1    20050922    AU 2005-222387           20050308
     CA 2558050             A1    20050922    CA 2005-2558050          20050308
     WO 2005087797          A1    20050922    WO 2005-US7752           20050308
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     EP 1730172             A1    20061213    EP 2005-732019           20050308
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     CN 101010335           A     20070801    CN 2005-80014557         20050308
     NO 2006004121          A     20061122    NO 2006-4121             20060913
PRIORITY APPLN. INFO.:                        US 2003-443098P      P   20030128
                                              US 2003-471288P      P   20030515
                                              US 2003-519460P      P   20031112
                                              US 2004-766735       A2  20040128
                                              US 2004-796719       A2  20040309
                                              US 2004-845895       A2  20040514
                                              US 2004-899806       A   20040727
```

US 2005-54071 A 20050208
WO 2005-US7752 W 20050308

OTHER SOURCE(S): MARPAT 146:55519
ED Entered STN: 15 Dec 2006
AB Peptides and other agents that activate the guanylate cyclase C (GC-C) receptor are provided for treating irritable bowel syndrome (IBS) and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or non-ulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction)), and disorders and conditions associated with constipation (e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders), as well as other conditions and disorders. The peptides, like the bacterial ST peptides, have six Cys residues which form 3 disulfide bonds in the mature and active form of the peptide. In particular, variant ST peptides (CCEYCSNPACTGCY and NSSNYCCEYCCNPACTGCY), and the wild-type ST peptide (NSSNYCCELCCNPACTGCY) are produced recombinantly or synthetically and tested in animal models. The peptides bind to the intestinal GC-C receptor, a key regulator of fluid and electrolyte balance in the intestine. When stimulated, this receptor, which is located on the apical membrane of the intestinal epithelial surface, causes an increase in intestinal epithelial cGMP. This increase in cGMP is believed to cause an increase in Cl- and K+ secretion, leading to changes in intestinal fluid and electrolyte transport and increased intestinal motility.
INCL 514013000; 530326000; 514015000; 514014000; 514282000; 514317000; 514355000; 514454000; 514618000
CC 1-9 (Pharmacology)
IT Ear
(inner, disorders; bacterial enterotoxin ST peptide variants activating guanylate cyclase C receptor useful in treatment of gastrointestinal disorders)

L97 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:78296 CAPLUS Full-text
DOCUMENT NUMBER: 142:170088
TITLE: Methods for the treatment of gastrointestinal disorders using guanylate cyclase C receptor activators, such as ST peptide variants
INVENTOR(S): Currie, Mark G.; Mahajan-Miklos, Shalina
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 83 pp., Cont.-in-part of U.S. Ser. No. 766,735.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005020811	A1	20050127	US 2004-796719	20040309
US 2004266989	A1	20041230	US 2004-766735	20040128
US 2006281682	A1	20061214	US 2004-845895	20040514
US 2006258593	A1	20061116	US 2004-899806	20040727
AU 2005222387	A1	20050922	AU 2005-222387	20050308
CA 2558050	A1	20050922	CA 2005-2558050	20050308
WO 2005087797	A1	20050922	WO 2005-US7752	20050308

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

EP 1730172	A1	20061213	EP 2005-732019		20050308
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 101010335	A	20070801	CN 2005-80014557		20050308
IN 2006DN05053	A	20070810	IN 2006-DN5053		20060901
NO 2006004121	A	20061122	NO 2006-4121		20060913
PRIORITY APPLN. INFO.:			US 2003-443098P	P	20030128
			US 2003-471288P	P	20030515
			US 2003-519460P	P	20031112
			US 2004-766735	A2	20040128
			US 2004-796719	A2	20040309
			US 2004-845895	A2	20040514
			US 2004-899806	A	20040727
			US 2005-54071	A	20050208
			WO 2005-US7752	W	20050308

OTHER SOURCE(S): MARPAT 142:170088
ED Entered STN: 28 Jan 2005
AB The present invention features compns. and related methods for treating irritable bowel syndrome (IBS) and other gastrointestinal disorders and conditions using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. The gastrointestinal disorders include gastrointestinal motility disorders, functional gastrointestinal disorders, gastro-esophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastro-paresis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders. Provided are sequences of the peptides of the invention , as well as a method for there preparation The peptides of the invention, like the bacterial ST peptides, have six Cys residues. These six Cys residues form three disulfide bonds in the mature and active form of the peptide. If the six Cys residues are identified, from the amino to carboxy terminus of the peptide, as A, B, C, D, E, and F, then the disulfide bonds form as follows: A-D, B-E, and C-F. The formation of these bonds is thought to be important for GC-C receptor binding. Certain of the peptides of the invention include a potentially functional chymotrypsin cleavage site. Cleavage at chymotrypsin cleavage site reduces or eliminates the ability of the peptide to bind to the GC-C receptor. It is expected that chymotrypsin cleavage will moderate the action of a peptide of the invention having an appropriately positioned chymotrypsin cleavage site as the peptide passes through the intestinal tract.
IC ICM C07K007-08
ICS C07K007-06
INCL 530327000; 530328000
CC 1-9 (Pharmacology)
IT Ear
(inner, disorder; methods for treatment of gastrointestinal disorders using guanylate cyclase C (GC-C) receptor activators, such as ST peptide variants)

L97 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:681510 CAPLUS Full-text
DOCUMENT NUMBER: 141:200192
TITLE: Methods and compositions using guanylate cyclase C receptor activators for the treatment of gastrointestinal disorders
INVENTOR(S): Currie, Mark G.; Mahajan-Miklos, Shalina
PATENT ASSIGNEE(S): Microbia, Inc., USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004069165	A2	20040819	WO 2004-US2390	20040128
WO 2004069165	A3	20050317		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004210161	A1	20040819	AU 2004-210161	20040128
CA 2514507	A1	20040819	CA 2004-2514507	20040128
EP 1594517	A2	20051116	EP 2004-706011	20040128
EP 1594517	B1	20070620		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007071	A	20060124	BR 2004-7071	20040128
CN 1795007	A	20060628	CN 2004-80008533	20040128
JP 2006516631	T	20060706	JP 2006-503109	20040128
AT 365174	T	20070715	AT 2004-706011	20040128
MX 2005PA08097	A	20060208	MX 2005-PA8097	20050728
IN 2005DN03394	A	20070601	IN 2005-DN3394	20050801
NO 2005003864	A	20051026	NO 2005-3864	20050818

PRIORITY APPLN. INFO.:	US 2003-443098P	P	20030128
	US 2003-471288P	P	20030515
	US 2003-519460P	P	20031112
	WO 2004-US2390	W	20040128

OTHER SOURCE(S): MARPAT 141:200192
ED Entered STN: 20 Aug 2004
AB The invention discloses compns. and related methods for treating irritable bowel syndrome (IBS) and other gastrointestinal disorders and conditions, e.g. gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
IC ICM A61K

CC 1-9 (Pharmacology)
IT Ear
(inner, disorder; guanylate cyclase C receptor activators for treatment of gastrointestinal disorders)

L97 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:82239 CAPLUS Full-text
DOCUMENT NUMBER: 138:163170
TITLE: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: A retrospective cohort study
AUTHOR(S): Francella, Andrew; Dyan, Alan; Bodian, Carol; Rubin, Peter; Chapman, Mark; Present, Daniel H.
CORPORATE SOURCE: Department of Medicine and Biostatistics, Mount Sinai Hospital Medical Center, New York, NY, USA
SOURCE: Gastroenterology (2003), 124(1), 9-17
CODEN: GASTAB; ISSN: 0016-5085
PUBLISHER: W. B. Saunders Co.
DOCUMENT TYPE: Journal
LANGUAGE: English
ED Entered STN: 03 Feb 2003
AB 6-Mercaptopurine/azathioprine is effective in IBD patients. However, data regarding toxicity associated with pregnancy are lacking, raising both patients' and physicians' concerns and sometimes resulting in elective abortion. To evaluate potential toxicity of 6-mercaptopurine (6-MP), we reviewed the records of 485 patients who had received the drug. We contacted 462, of whom 155 had conceived at least 1 pregnancy after developing IBD. Pregnancies were analyzed as to whether the patient had taken 6-MP before, or at the time of, conception. These were compared with IBD patients who had their pregnancies before taking 6-MP. We collected data on live births, spontaneous abortions, prematurity, abortions secondary to birth defects, major and minor congenital birth defects, infections, and neoplasia. Outcomes were analyzed comparing pregnancies from men and women who had taken or were currently taking 6-MP to controls. There was no statistical difference in conception failures (defined as a spontaneous abortion), abortion secondary to a birth defect, major congenital malformations, neoplasia, or increased infections among male or female patients taking 6-MP compared with controls (RR = 0.85 [0.47-1.55], P = 0.59). 6-MP use before or at conception or during pregnancy appears to be safe. Discontinuation of the drug before and during pregnancy is not indicated.
CC 1-7 (Pharmacology)
IT Ear, disease
Inflammation
(otitis media, infant infection; 6-mercaptopurine effect on pregnancy outcome in male and female patients with inflammatory bowel disease)
REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L97 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:627982 CAPLUS Full-text
DOCUMENT NUMBER: 133:213188
TITLE: Compositions for the treatment of neuropathic pain, tinnitus, and other disorders with R-(-)-ketoprofen
INVENTOR(S): Jerussi, Thomas P.; Rubin, Paul D.
PATENT ASSIGNEE(S): Sepracor Inc., USA
SOURCE: PCT Int. Appl., 26 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000051595	A1	20000908	WO 2000-US5170	20000301
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6362227	B1	20020326	US 2000-507470	20000222
CA 2362489	A1	20000908	CA 2000-2362489	20000301
EP 1156794	A1	20011128	EP 2000-915921	20000301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003520193	T	20030702	JP 2000-602063	20000301
US 2002147238	A1	20021010	US 2002-62766	20020205
US 6620851	B2	20030916		
US 2004019111	A1	20040129	US 2003-620704	20030717

PRIORITY APPLN. INFO.:	US 1999-122382P	P	19990302
	US 2000-507470	A	20000222
	WO 2000-US5170	W	20000301
	US 2002-62766	A3	20020205

ED Entered STN: 10 Sep 2000

AB Methods of treating neuropathic pain, tinnitus, and related disorders are disclosed. These methods comprise the administration of optically pure R(-)-ketoprofen compns. Tablets contained R-(-)-ketoprofen 20, lactose 134.5, starch 30, pregelatinized corn starch 15, and Mg stearate 0.5 g.

IC ICM A61K031-19
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
ST ketoprofen enantiomer neuropathic pain; tinnitus ketoprofen enantiomer
IT Nervous system
(Guillain-Barre syndrome; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)
IT Antibiotics
(aminoglycoside; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)
IT Brain
(cerebellum, disease; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)
IT Movement disorders
(cerebral palsy; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)
IT Analgesics
Anemia (disease)
Aneurysm
Arteriosclerosis
Cardiovascular agents
Diuretics
Hypertension
Hypothyroidism

Meningitis
Syphilis
(compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Heavy metals
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Cardiovascular system
Spinal cord
(disease; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Ear
(inner, labyrinthitis; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Nerve, disease
(neuropathy, pain from; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Ear
(otitis; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Nerve, disease
(peripheral, injury; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Brain
(stem, disease; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Drug delivery systems
(tablets; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Brain
(thalamus, disease; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Ear
(tinnitus; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT Injury
(trauma; compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT 63-36-5D, Salicylate, derivs., biological studies 130-95-0, Quinine 630-08-0, Carbon monoxide, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

IT 56105-81-8, (-)-Ketoprofen 56105-81-8D, (-)-Ketoprofen, salts or solvates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment of neuropathic pain and tinnitus with R-(-)-ketoprofen)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L87 ANSWER 6 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-507771 [49] WPIX
CROSS REFERENCE: 2007-459404; 2007-477340; 2007-507772; 2007-507773

DOC. NO. CPI: C2007-186592 [49]
TITLE: New Streptococcus pneumoniae immunogenic composition comprises capsular saccharides from different S. pneumoniae serotypes, useful for treating or preventing S. pneumoniae infection, e.g. pneumonia or otitis media
DERWENT CLASS: B04; D16
INVENTOR: BIEMANS R L; GARCON N M; HERMAND P V; POOLMAN J; VAN MECHELEN M P
PATENT ASSIGNEE: (GLAX-C) GLAXOSMITHKLINE BIOLOGICALS SA
COUNTRY COUNT: 116

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007071707	A2	20070628	(200749)*	EN	91[10]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007071707	A2	WO 2006-EP69974	20061220

PRIORITY APPLN. INFO:

WO 2006-GB4634	20061212
GB 2005-26232	20051222
GB 2006-7087	20060407
GB 2006-7088	20060407
GB 2006-9902	20060518
GB 2006-20336	20061012
GB 2006-20337	20061012
GB 2006-20815	20061019
GB 2006-20816	20061019

AB WO 2007071707 A2 UPAB: 20070801
NOVELTY - A S. pneumoniae immunogenic composition comprising 9-14 or more capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to Diphtheria toxoid (DT) or CRM197, where 19F is the only saccharide in the composition conjugated to diphtheria toxoid DT or CRM197, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for: (1) a vaccine kit comprising the immunogenic composition and further comprising for concomitant or sequential administration an adjuvant;
(2) a vaccine comprising the immunogenic composition and a pharmaceutical excipient;
(3) a process for making the vaccine comprising mixing the immunogenic composition with a pharmaceutical excipient; (4) a method of immunizing a human host against disease caused by S. pneumoniae infection;
(5) a method of eliciting a protective immune response in infants against otitis media; and
(6) a method of eliciting a protective immune response to infants or elderly against S. pneumoniae.
ACTIVITY - Antibacterial; Antiinflammatory; Respiratory-Gen; Auditory; Neuroprotective; Ophthalmological. No biological data given.
MECHANISM OF ACTION - Vaccine.
USE - The immunogenic composition or vaccine is useful for the treatment or prevention of disease caused by S. pneumoniae infection, or in the manufacture of a medicament for the treatment or prevention of diseases caused by S. pneumoniae infection. The disease is pneumonia, invasive pneumococcal disease (IPD), or chronic obstructive pulmonary disease (COPD) of elderly humans. The

disease is otitis media, meningitis and/or bacteremia, or conjunctivitis of infant humans (all claimed).

L87 ANSWER 7 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-504805 [49] WPIX
CROSS REFERENCE: 2005-194991; 2005-532171; 2007-342309
DOC. NO. CPI: C2007-185438 [49]
TITLE: Treating otitis externa in a human patient comprises topically administering liquid ear drop composition to Aspergillus-affected external ear canal of human patient
DERWENT CLASS: B05; C03
INVENTOR: LANE E M
PATENT ASSIGNEE: (FAIR-N) FAIRFIELD CLINICAL TRIALS LLC
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20070078116	A1	20070405	(200749)*	EN	11[4]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20070078116	A1 Provisional	US 2003-496409P	20030820
US 20070078116	A1 Provisional	US 2003-505754P	20030926
US 20070078116	A1 CIP of	US 2004-771330	20040205
US 20070078116	A1	US 2006-543203	20061005

PRIORITY APPLN. INFO: US 2006-543203 20061005
US 2003-496409P 20030820
US 2003-505754P 20030926
US 2004-771330 20040205

AB US 20070078116 A1 UPAB: 20070801
NOVELTY - Treating otitis externa in a human patient comprises topically administering liquid ear drop composition to the Aspergillus-affected external ear canal of human patient. The liquid ear drop composition comprises antifungal, a corticosteroid anti-inflammatory agent and an acidifying agent. The otistis externa is caused by Aspergillus species.
ACTIVITY - Auditory.
Itraconazole (1%) solution in a vehicle containing glacial acetic acid (2%), hydrocortisone (1%), benzalkonium chloride (0.02%), sodium acetate trihydrate (0.015%), and citric acid (0.2%) in propylene glycol or vehicle alone was administered four (4) drops in the affected ear twice daily for 10 days to patients diagnosed with otitis externa. Six out of the seven patients receiving the 1% Itraconazole solution were cured, with the ear canal drying up within 3-5 days; symptom relief was achieved by 3-5 days with complete remission of disease seen at 12-15 days (cure). These patients remained disease free at 18-21 days. Vehicle alone was ineffective at curing fungal otitis externa in all but one case.
MECHANISM OF ACTION - None given.
USE - The method is useful for treating otitis externa in human patient.
ADVANTAGE - The composition decreases the incidence of candidiasis in patient undergoing bone marrow transplantation who receives cytotoxic chemotherapy and/or radiation therapy.

L87 ANSWER 8 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-496087 [48] WPIX
DOC. NO. CPI: C2007-182781 [48]
TITLE: New dihydropseudo erythromycin derivative, useful for prevention-treatment of inflammatory disease e.g. inflammatory bowel disease, Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease or sinusitis
DERWENT CLASS: B02
INVENTOR: NAGAI K; OMURA S; SHIMA H; SUNAZUKA T; YAMABE H
PATENT ASSIGNEE: (KITA-C) KITASATO INST; (APHO-N) APHOENIX INC
COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007043710	A1	20070419	(200748)*	JA	100[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007043710	A1	WO 2006-JP320888	20061013

PRIORITY APPLN. INFO: JP 2005-301070 20051014

AB WO 2007043710 A1 UPAB: 20070727
NOVELTY - Dihydropseudo erythromycin derivative (I) or its salt is new.
DETAILED DESCRIPTION - Dihydropseudo erythromycin derivative of formula (I) or its salt is new.
Me=methyl;
R1,R2=H, alkyl, acyl, sulfonyl, (un)substituted aryl substituted alkyl, aryl substituted alkyl oxycarbonyl, alkenyl or alkynyl, or R1 and R2 combine with adjoining nitrogen atom to form optionally substituted alicyclic heterocyclic group;
R3=H, optionally substituted acyl or aryl substituted alkyl oxycarbonyl;
A=H;
B=hydroxyl or group of formula (II), or A and B combine to form =O; R4=H or acyl;
R=group of formula (III) or (V), or Me-C(=D)-; R5,R6=H or acyl, or R5 and R6 combine to form carbonyl or optionally substituted alkylene; and D=O, H, OH or N-OH.
An INDEPENDENT CLAIM is included for commercial package containing the documents, describing that the preventive-therapeutic agent of inflammatory disease contains the compound (I) or its salt as an active ingredient, and the agent is used for the prevention-treatment of inflammatory disease.
ACTIVITY - Antiinflammatory; Gastrointestinal-Gen.; Antiulcer; Respiratory-Gen.; CNS-Gen.; Auditory; Antipsoriatic; Uropathic. Trinitro benzene sulfonic-acid (TNBS) solution was injected into rectum of 8 weeks old SD type male rats under pentobarbital anesthesia and colitis model was produced. Fecal-occult-blood score was measured after two days of TNBS administration. De(3'-dimethylamino)-3'-morpholino-9- dihydro-pseudoerythromycin A 6,9-epoxide (Ia) was administered orally to the animal model twice a day for six days. Large intestine was extracted, the grade of damage was scored according to method specified in Wallace, J.L et al, Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease, Gastroenterology 96,29 36 (1989), and drug efficacy was evaluated. (Ia) Exhibited an ulcer inflammation score of 2.93plus minus0.41 in rats in a TNBS induced colitis assay. (Ia) Had excellent TNBS induced large intestine-ulcer improving effect.

MECHANISM OF ACTION - None given.
USE - For manufacturing pharmaceutical for prevention-treatment of inflammatory disease e.g. inflammatory bowel disease (claimed) such as Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease, chronic bronchitis, respiratory-disease, cystic fibrosis, diffuse panbronchiolitis, pneumonia, lung fibrosis, sinusitis, bronchiectasis, paranasal-sinuses bronchial syndrome, interstitial pneumonia, otitis-media-with-effusion (exudative otitis media), psoriasis, frequent urination (pollakiuria) and interstitial cystitis.
ADVANTAGE - The new dihydropseudo erythromycin derivative has excellent stability with respect to acid and excellent antiinflammatory activity.

L87 ANSWER 9 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-495632 [48] WPIX
DOC. NO. CPI: C2007-182653 [48]
TITLE: Treating or preventing a middle ear infection e.g. otitis media involves transmembrane administration of a carrier composition comprising a medicament and a non-ionic surfactant to the tympanic membrane
DERWENT CLASS: A96; B02
INVENTOR: CAMPBELL W R; JOHNSON R H; PAULSEN N E
PATENT ASSIGNEE: (PIED-N) PIEDMONT PHARM LLC
COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007037886	A2	20070405	(200748)*	EN	13[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007037886	A2	WO 2006-US33598	20060825

PRIORITY APPLN. INFO: US 2005-720536P 20050926
AB WO 2007037886 A2 UPAB: 20070727
NOVELTY - Treating or preventing a middle ear infection involves applying a transmembrane carrier composition comprising a medicament, to the outer surface of the tympanic membrane.
ACTIVITY - Auditory; Analgesic; Antiinflammatory. A transmembrane carrier composition comprising: ciprofloxacin hydrochloride, monohydrate dexamethasone alcohol, hydroxyethyl cellulose, benzalkonium chloride, sodium acetate, (trihydrate) acetic acid, sodium chloride, ethylene diamine tetra acetic acid, tyloxapol, glycerin, boric acid, sodium hydroxide/hydrochloric acid and purified water was administered orally (2 - 6 drops) twice per day for 6 days, approximately 8 hours apart, by gavage to chinchillas suffering from middle ear infection, while a second group of chinchillas did not receive anything (control). The animals were then examined. The results showed the number of ears infected/total number ears was 7/10 for control group while no infection was observed in test group. This demonstrates the efficacy of the composition in treating middle ear infection
MECHANISM OF ACTION - None given.
USE - For treating or preventing a middle ear infection (claimed) e.g. otitis media in mammals including humans.
ADVANTAGE - The carrier composition comprising nonionic polymer surfactant and medicament can be delivered across an intact tympanic membrane i.e. one

without tears (e.g. from bursting under pressure) or punctures (e.g. from insertion of tubes or injection). The nonionic polymer surfactants when applied to the tympanic membrane facilitates the transport of a medicament across the membrane and into the middle ear and also modifies the porosity and thus permeability of the tympanic membrane by a magnitude sufficient to permit the medicament to pass into the membrane. The carrier composition is effective in treating middle ear infections and its associated pain and inflammation.

L87 ANSWER 10 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-492968 [48] WPIX
DOC. NO. CPI: C2007-181704 [48]
DOC. NO. NON-CPI: N2007-374956 [48]
TITLE: Device for delivery of therapeutic agents e.g. neurotrophic agent and antibiotic, comprises body having proximal and distal ends with cavity, access port located at proximal end and removable insert
DERWENT CLASS: A96; B07; D22; P32
INVENTOR: WEN X
PATENT ASSIGNEE: (UYCL-N) UNIV CLEMSON
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20070077270	A1	20070405	(200748)*	EN	17	[7]

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20070077270	A1 Provisional	US 2005-665711P	20050328
US 20070077270	A1	US 2006-390958	20060328

PRIORITY APPLN. INFO: US 2006-390958 20060328
US 2005-665711P 20050328

AB US 20070077270 A1 UPAB: 20070727
NOVELTY - A drug delivery device (10) comprises a body (20) having a proximal end and a distal end (22, 24) with a cavity, an access port (30) located at the proximal end and a removable insert. The removable insert has a proximal end and a distal end. The removable insert is configured to be removably inserted into the cavity of body.
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is included for a method of targeted delivery of therapeutic agent to inner ear or eye.
USE - For delivering therapeutic agent such as a neurotrophic agent or an antibiotic (claimed) for treating ocular diseases e.g. retinal degeneration, retinal detachment, proliferative retinopathy and proliferative diabetic retinopathy and inner ear diseases e.g. deafness, sensorineural hearing loss, autoimmune inner ear disease, Meniere's disease, tinnitus, otitis, otalgia, and other otic diseases.
ADVANTAGE - The device efficiently delivers the therapeutic agent into inner ear or eye.
DESCRIPTION OF DRAWINGS - The figure shows the structure of body of the delivery device.
Delivery device (10)
Body (20)
Distal and proximal end (22,24) Access port (30)

L87 ANSWER 11 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-485683 [48] WPIX
DOC. NO. CPI: C2007-178604 [48]
DOC. NO. NON-CPI: N2007-368948 [48]
TITLE: Film for tissue culture reproduction occlusion of eardrum perforation used in surgical treatment of e.g. chronic otitis, has activator mixed with atherocollagen film for eardrum and impregnated with concentrated blood platelets plasma
DERWENT CLASS: B04; P32; P34
INVENTOR: YOSHIDA K
PATENT ASSIGNEE: (YOSH-I) YOSHIDA K
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
JP 2007075136	A	20070329	(200748)*	JA	4[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 2007075136	A	JP 2005-262707	20050909

PRIORITY APPLN. INFO: JP 2005-262707 20050909
AB JP 2007075136 A UPAB: 20070727
NOVELTY - The film contains an activator that consists of self-thrombin and calcium chloride, and that is mixed with atherocollagen film with 1 to 2 millimeter thickness for eardrum. The activator is impregnated with 0.1 to 0.3 milliliter of concentrated blood platelets plasma (PRP) extracted twice from the patient's autologous blood using centrifuge method.
USE - For tissue culture reproduction occlusion of eardrum perforation used in surgical treatment of e.g. chronic otitis, tympanotomy, eardrum tube indwelling.
ADVANTAGE - Provides a simple and cost-effective technique for the occlusion of eardrum perforation. Provides a very effective therapeutic procedure for patients, especially children, who hesitate in surgery.

L87 ANSWER 12 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-476533 [46] WPIX
DOC. NO. CPI: C2007-173933 [46]
DOC. NO. NON-CPI: N2007-362212 [46]
TITLE: Assessing a patient's risk of developing otitis media (OM) or its progression or assisting in the diagnosis of OM by determining the amount or function of FBXO11 polypeptide or nucleic acid and the patient's genotype for FBXO11
DERWENT CLASS: B04; D16; S03
INVENTOR: BROWN S D M; HARDISTY-HUGHES R E
PATENT ASSIGNEE: (MEDI-N) MEDICAL RES COUNCIL
COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007039759	A1	20070412	(200746)*	EN	71[6]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007039759 A1		WO 2006-GB3731	20061006

PRIORITY APPLN. INFO: GB 2005-20311 20051006

AB WO 2007039759 A1 UPAB: 20070719

NOVELTY - Assessing a patient's risk of developing otitis media (OM) or progression of OM or assisting in the diagnosis of OM, comprises (i) obtaining a sample containing nucleic acid and/or protein from the patient; and (ii) determining one or more of: (a) the amount and/or function of FBXO11 polypeptide; (b) the amount of nucleic acid encoding FBXO11; and (c) the patient's genotype for FBXO11.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are: (1) use of an agent which is capable of being used in determining one or more of the amount or function of FBXO11 polypeptide or nucleic acid encoding FBXO11, and determining a patient's genotype of FBXO11, in manufacturing a reagent for assessing a patient's risk of developing otitis media (OM); or progression of OM, or for assisting in the diagnosis of OM;

(2) an expression vector comprising a polynucleotide which encodes FBXO11 polypeptide;

(3) a host cell comprising the expression vector; (4) a method of making a FBXO11 polypeptide, or a variant, fragment, derivative or fusion or fusion of a the variant or fragment or derivative;

(5) a gene therapy vector comprising a polynucleotide which encodes FBXO11 polypeptide;

(6) a pharmaceutical composition comprising a polynucleotide encoding FBXO11 or FBXO11 polypeptide or a gene therapy vector and a pharmaceutically acceptable carrier; (7) a polynucleotide encoding FBXO11 or FBXO11 polypeptide, gene therapy vector or pharmaceutical composition for use in medicine; (8) a method of treating a patient with or at risk of developing OM by administering to the patient an appropriate quantity of a polynucleotide encoding FXBO11 or FBXO11 polypeptide, gene therapy vector or pharmaceutical composition;

(9) a method for generating a non-human animal which develops OM; (10) an isolated or recombinant nucleic acid encoding FBXO11 in which the residue corresponding to Q491 is mutated, for example to L; or in which the residue corresponding to S244 is mutated, e.g., to L; (11) a method for identifying a putative substrate polypeptide for FBXO11 polypeptide;

(12) a method for identifying a polypeptide involved in OM; (13) a method of generating a non-human animal which develops OM; (14) a kit of parts useful for assessing a patient's risk of developing otitis media (OM); or progression of OM; or for assisting in the diagnosis of OM, comprising one or more agents useful in determining one or more of: (a) the amount or function of FBXO11 polypeptide; (b) the amount of nucleic acid encoding FBXO11; (c) the patient's genotype for FBXO11; and, optionally, (d) a positive or negative control; and (15) a method for identifying a compound expected to be useful in treating or preventing OM.

ACTIVITY - Auditory. No biological data given.

MECHANISM OF ACTION - Vaccine.

USE - The agent which is capable of being used in determining one or more of the amount or function of FBXO11 polypeptide or nucleic acid encoding FBXO11, and determining a patient's genotype of FBXO11, in manufacturing a reagent for assessing a patient's risk of developing otitis media (OM); or progression of OM, or for assisting in the diagnosis of OM. The polynucleotide encoding FBXO11 or FBXO11 polypeptide, gene therapy vector or pharmaceutical composition is useful in manufacturing a medicament for treating or preventing

OM. The modulator, e.g., inhibitor of an E3 ubiquitin ligase is useful in manufacturing a medicament for treating or preventing acute or chronic OM.

L87 ANSWER 13 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-473752 [46] WPIX
DOC. NO. NON-CPI: N2007-359731 [46]
TITLE: Method for preventing atrophic retraction and adhesion of tympanic membrane taking place in exudative otitis cases
DERWENT CLASS: P32
INVENTOR: ANIKIN I A; ANIKIN M I; CHERNUSHEVICH I I; DIAB KH; SITNIKOV V P
PATENT ASSIGNEE: (SPET-R) ST PETERSBURG EAR THROAT SPEECH RES INST
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
RU 2302223	C1	20070710	(200746)*	RU	[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
RU 2302223 C1		RU 2005-134517	20051101

PRIORITY APPLN. INFO: RU 2005-134517 20051101
AB RU 2302223 C1 UPAB: 20070719
NOVELTY - Method involves inspecting tympanic cavity with cicatrices and polyps being removed, isolating tympanic membrane from middle ear structures, and strengthening atrophied membrane segment by means of a support member. Soft tissues are separated in mastoid process and external acoustic meatus posterior wall skin area, meatotympanic graft is detached, the tympanic membrane is isolated and its atrophied membrane is strengthened in one stage with one element like 40-50 mcm thick allotendon plate. One edge of the plate is set with a support on posterior wall bone of external acoustic meatus and fixed with external acoustic meatus skin when returning the meatotympanic graft on a its place, retaining the other edge in partially mobile state adjoining to tympanic membrane internal surface and overlapping the atrophied site by 0.5-1 mm.
USE - Medicine.
ADVANTAGE - Avoided repeated surgical intervention.2 cl, 2 dwg

L87 ANSWER 14 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-445302 [43] WPIX
CROSS REFERENCE: 2004-439866
DOC. NO. CPI: C2007-161837 [43]
TITLE: Medical kit for use in treating middle and inner ear conditions, e.g. otitis media, comprises flowable aqueous formulation containing viscogenic agent and pharmacologic agent(s), and instructions for using formulation
DERWENT CLASS: A96; B02; B03; B07
INVENTOR: CHEUNG B W Y; SAWCHUK R J
PATENT ASSIGNEE: (MINU-C) UNIV MINNESOTA
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
US 20070098679	A1	20070503	(200743)*	EN	10[2]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 20070098679	A1 Cont of	US 2002-306517	20021127
US 20070098679	A1	US 2006-614266	20061221

PRIORITY APPLN. INFO: US 2006-614266 20061221
US 2002-306517 20021127

AB US 20070098679 A1 UPAB: 20070706
NOVELTY - A medical kit comprises an aqueous formulation, and instructions indicating that the formulation is to be applied to a tympanic membrane. The formulation contains viscogenic agent and pharmacologic agent(s), is flowable and has a viscosity of less than 100000 cPs. After application to the tympanic membrane, the formulation forms a gel having a yield stress sufficient to maintain the formulation against the tympanic membrane. The formulation allows for transfer of pharmacologic agent across the tympanic membrane and into the middle ear space.
ACTIVITY - Auditory. No biological data given.
MECHANISM OF ACTION - None given.
USE - For applying aqueous formulation to the ear for treating middle and inner ear conditions, e.g. otitis media.
ADVANTAGE - Delivery of aqueous composition to the tympanic membrane provides more effective ways to treat middle and inner ear disorders, e.g. otitis media.

L87 ANSWER 15 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-434428 [41] WPIX
CROSS REFERENCE: 2007-533740
DOC. NO. CPI: C2007-157584 [41]
TITLE: New piperidine derivatives are chemokine receptor 1 inhibitors useful for the treatment of e.g. inflammatory condition, immunoregulatory disorder, rheumatoid arthritis and multiple sclerosis
DERWENT CLASS: B02; B03; D22
INVENTOR: CHEN W; GREENMAN K L; LI L; PENNELL A; PENNELL A M K; SULLIVAN E J; ZHANG P; ARALDI G; ROHSHEIM M
PATENT ASSIGNEE: (CHEM-N) CHEMOCENTRYX INC
COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007044804	A2	20070419	(200741)*	EN	86[7]	
US 20070088036	A1	20070419	(200741)	EN		
US 20070093467	A1	20070426	(200741)	EN		
WO 2007073432	A2	20070628	(200746)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 2007044804 A2	WO 2006-US39713 20061011
US 20070088036 A1 Provisional	US 2005-725980P 20051011
US 20070093467 A1 Provisional	US 2005-725980P 20051011
US 20070088036 A1	US 2006-546938 20061011
US 20070093467 A1	US 2006-580202 20061011
WO 2007073432 A2	WO 2006-US39980 20061011

PRIORITY APPLN. INFO: US 2005-725980P 20051011
US 2006-546938 20061011
US 2006-580202 20061011

AB WO 2007044804 A2 UPAB: 20070629

NOVELTY - Piperidine derivatives (I) and their salts and N-oxides are new.

DETAILED DESCRIPTION - Piperidine derivatives of formula (I) and their salts and N-oxides are new.

R1=e.g. 1-8C alkyl or 1-8C haloalkyl; m'=0 - 4;

R2a-R2e=e.g. H, halo, -CN or -NO2; B'=e.g. (hetero)aryl (optionally substituted with 1-5 R3); R3=e.g. halo, -CN or -NO2;

L1=e.g. 1-4C alkylene or heteroalkylene;and A=e.g. H or (hetero)aryl.

The full definitions are given in the DEFINITIONS (Full Definitions) field.

INDEPENDENT CLAIMS are included for the following: (1) a pharmaceutical composition (C1) comprising (I) and excipient or carrier; and

(2) treatment (m1) of chemokine receptor 1 (CCR1)-mediated diseases or conditions involving administering the piperidine derivative (I). ACTIVITY - Antiinflammatory; Antirheumatic; Antiarthritic; Dermatological; Neuroprotective; Nootropic; Immunosuppressive; Vasotropic; Gastrointestinal-Gen.; Antiallergic; Antiasthmatic; Antiparkinsonian; Antipsoriatic; Osteopathic; Cerebroprotective; Antiulcer; Antipruritic; Respiratory-Gen.; Antidiabetic; Nephrotropic; Hepatotropic; Cardiovascular-Gen.; Antiarteriosclerotic; Antiangiogenic; Virucide; Antibacterial; Ophthalmological; Auditory; Vulnerary; Anti-HIV; Cytostatic.

MECHANISM OF ACTION - Chemokine receptor 1 (CCR1) inhibitor. Inhibition of CCR1 ligand binding by 1-(2-(4-chloro-5-methyl-3- trifluoromethyl-pyrazol-1-yl)-acetyl)-4-(4-chloro-phenyl)-piperidine-4- carbonitrile (IA) was tested as follows: CCR1 expressing cells were centrifuged and resuspended in assay buffer containing 4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid (HEPES) (20 mM) pH 7.1, NaCl (140 mM), CaCl2 (1 mM), MgCl2 (5 mM), and with bovine serum albumin (0.2%) to a concentration of 5x106 cells/ml for THP (tetrahydropyran)-1 cells and 5x105 for monocytes. The cells (0.1 ml) were added to the assay plates containing (IA). Then 125I labeled macrophage inflammatory protein (MIP)-1alpha (0.1 ml) or 125I labeled CCL15 (chemokine leukotactin)/leukotactin (0.1 ml) diluted in assay buffer was added and the plates were sealed and incubated for 3 hours at 4degreesC. The reactions were aspirated in polyethyleneimine (PEI) solution (0.3%). The IC50 value for (IA) was calculated, which was found to be less than 1000 nM.

USE - For the treatment of CCR1-mediated diseases or conditions e.g. inflammatory condition, immunoregulatory disorder, rheumatoid arthritis, multiple sclerosis, transplant rejection, restenosis, dermatitis, eczema, urticaria, vasculitis, inflammatory bowel disease, food allergy, asthma, Alzheimer's disease, Parkinson's disease, psoriasis, lupus erythematosus, osteoarthritis, stroke and encephalomyelitis (all claimed); for the treatment of diseases associated with CCR1, CCR2 and CCR3 signaling activity; for the treatment of diseases or conditions including chronic diseases of human or other species can be treated with modulators of CCR1, CCR2 or CCR3 function (e.g. allergic diseases such as systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies; Crohn's disease, ulcerative colitis; vaginitis; allergic contact dermatitis, pruritus; spondyloarthropathies; respiratory allergic diseases such as hypersensitivity lung diseases; Still's disease, type I diabetes, type II diabetes, type I diabetes (recent onset), optic neuritis, graft rejection including allograft rejection and acute and chronic graft-versus-host disease; hepatic fibrosis

(including that caused by alcoholic or viral hepatitis), primary and secondary cirrhosis); other diseases in which undesired inflammatory responses or immune disorders are to be inhibited, such as cardiovascular disease including atherosclerosis, vascular inflammation resulting from tissue transplant or during restenosis (including restenosis following angioplasty and/or stent insertion), other acute and chronic inflammatory conditions such as myositis, neurodegenerative diseases (e.g. Alzheimer's disease), encephalitis, meningitis, hepatitis, nephritis, sepsis, allergic conjunctivitis, otitis, sinusitis, synovial inflammation caused by arthroscopy, hyperuremia, trauma, ischemia reperfusion injury, nasal polyosis, preeclampsia, oral lichen planus, Guillain-Barre syndrome, granulomatous diseases, conditions associated with leptin production, Behcet's syndrome and gout and in wound healing applications; immune mediated food allergies such as Celiac disease); for the treatment of diseases or conditions treated with modulators of CCR1 function (e.g. cancers (both primary and metastatic); infectious diseases (viral infections, e.g. HIV infection, and bacterial infections) and immunosuppressive diseases such as organ transplant conditions and skin transplant conditions); and in assays for the identification of competitive CCR1 antagonists.

ADVANTAGE - The compounds are potent antagonists of CCR1 receptors and have in vivo anti-inflammatory activity.

L87 ANSWER 16 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-414040 [40] WPIX
DOC. NO. CPI: C2007-150338 [40]
TITLE: Medicine for treating otitis media
DERWENT CLASS: B04; B07
INVENTOR: GUAN R; LIU T
PATENT ASSIGNEE: (LIUT-I) LIU T
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
CN 1903218	A	20070131	(200740)*	ZH	[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 1903218	A	CN 2006-10041264	20060730

PRIORITY APPLN. INFO: CN 2006-10041264 20060730
AB CN 1903218 A UPAB: 20070625
NOVELTY - A Chinese medicine in the form of powder for treating tympanitis is proportionally prepared from realgar, sulfur, roasted alum, sliced plum and musk through proportional mixing, breaking, grinding, and sieving.

L87 ANSWER 17 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-413117 [39] WPIX
DOC. NO. CPI: C2007-149643 [39]
TITLE: New substituted benzofused compounds are vanilloid receptor antagonists useful to prevent/ameliorate/treat e.g. asthma, ulcerative colitis, urinary incontinence and chronic pain
DERWENT CLASS: B02
INVENTOR: GHARAT L A; JOSHI N K; JOSHI U M

PATENT ASSIGNEE: (GLEN-N) GLENMARK PHARM SA
COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007042906	A1	20070419	(200739)*	EN	121[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007042906	A1	WO 2006-IB2814	20061009

PRIORITY APPLN. INFO: US 2006-807205P 20060713
IN 2005-MU1269 20051007
US 2005-730660P 20051026
IN 2006-MU996 20060626

AB WO 2007042906 A1 UPAB: 20070620
NOVELTY - Substituted benzofused compounds (I) and their analogs, salts, solvates, hydrates, N-oxides, tautomers, regioisomers, stereoisomers, prodrugs and polymorphs are new.
DETAILED DESCRIPTION - Substituted benzofused compounds of formula (I) and their analogs, salts, solvates, hydrates, N-oxides, tautomers, regioisomers, stereoisomers, prodrugs and polymorphs are new. X, Y1 = O, S(O)m or NRe; R1R2 = optionally substituted and saturated 3-7 membered cyclic ring (optionally include heteroatoms of O, NR9 or S(O)m); either R3, R4 = alkyl (optionally substituted), H, CN, halo, OR9 or NR9R10; or R3+R4 = oxo; either
R5-R7 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclylalkyl (all optionally substituted), H, NO2, CN, halo, OR9, NR9R10, C(=L)-R9, C(O)O-R9, C(O)NR9R10, S(O)m-R9 or S(O)m-NR9R10; either
R8 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl,cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclylalkyl (all optionally substituted), NR9R10, C(=L)-R9, C(O)O-R9, C(O)NR9R10, S(O)m-R9 or S(O)m-NR9R10 or H; or R7+R8 = optionally substituted and saturated 3-7 membered cyclic ring (optionally include 0-2 heteroatoms of O, NRe or S); either R9, R10 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclylalkyl (all optionally substituted), H, ORa, SRa, NRaRb, C(=L)-Ra, C(O)O-Ra, C(O)NRaRb, S(O)m-Ra or S(O)m-NRaRb; or NR9+R10 = 3-7 membered cyclic ring (optionally include at least two heteroatoms of O, NRe or S); either Ra, Rb = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclylalkyl (all optionally substituted), H, ORc, SRc, C(=L)-Rc, C(O)O-Rc, C(O)NRcRd, S(O)m-Rc, S(O)m-NRcRd, NRcRd or protecting group; or
NRa+Rb = optionally substituted and saturated 3-7 membered cyclic ring (optionally include at least two heteroatoms of O, NRe or S); either Rc, Rd = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, arylalkyl, (hetero)aryl, heteroarylalkyl, heterocyclic, heterocyclylalkyl (all optionally substituted), H or protecting group; or
NRc+Rd = 3-7 membered cyclic ring, optionally include at least two heteroatoms from O, NRe or S;
Re = alkyl (optionally substituted) or H; L = O, S or NRe;
m = 0-2; and
n = 0-4.

An INDEPENDENT CLAIM is included for the preparation of (I). ACTIVITY - Uropathic; Antiinflammatory; Antiasthmatic; Antiulcer; Gastrointestinal-Gen; Analgesic; antiinflammatory; gastrointestinal-gen.; Immunosuppressive; Antiallergic; Respiratory-Gen; Dermatological; Antipruritic; Anticonvulsant; Antiemetic; Muscular-Gen ; Antidepressant; Nootropic; Cerebroprotective ; Neuroprotective; Antiarthritic; Osteopathic; Antidiabetic; Anorectic; keratolytic; dermatological; Endocrine-Gen; Auditory; Tranquilizer; Cytostatic; Ophthalmological; Vasotropic; Gynecological.
MECHANISM OF ACTION - Vanilloid receptor 1 antagonist. The ability of (I) to antagonize vanilloid receptor 1 was tested using a 45 calcium uptake assay. The result showed that the percentage inhibition of vanilloid receptor 1 by (plus minus)1 (3,4-dihydro-1'- (methyl)spiro-(2H-1-benzopyran-2,4'-piperidine)-4-yl)-3-(isoquinoline-5- yl)urea was 142.29% at 1 muM.
USE - (I) are useful to prevent/ameliorate/treat a vanilloid receptor mediated disease, disorder or syndrome, where the disease, disorder or syndrome is urinary incontinence, inflammation, asthma, ulcerative colitis, pain such as acute pain, chronic pain, neuropathic pain, post-operative pain (all preferred), nociceptive pain, dental pain, cancer pain, cardiac pain arising from an ischemic myocardium, pain due to migraine, arthralgia, neuropathies, neuralgia and trigeminal neuralgia nerve injury, diabetic neuropathy, neurodegeneration, retinopathy, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, vulvodynia, gastrointestinal disorders such as irritable bowel syndrome, gastro-esophageal reflux disease, enteritis, ileitis, stomach-duodenal ulcer, inflammatory bowel disease, Crohn's disease, celiac disease, inflammatory disease (such as pancreatitis), respiratory disorder such as allergic and non-allergic rhinitis, chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, dermatitis, pruritic conditions such as uremic pruritus, fervescence, muscle spasms, emesis, dyskinesias, depression, Huntington's disease, memory deficits, restricted brain function, amyotrophic lateral sclerosis, dementia, arthritis, osteoarthritis, diabetes, obesity, urticaria, actinic keratosis, keratocanthoma, alopecia, Meniere's disease, tinnitus, hyperacusis , anxiety disorders and benign prostate hyperplasia (claimed).
ADVANTAGE - (I) are effective and safe to treat diseases, conditions and/or disorders modulated by vanilloid receptors.

L87 ANSWER 18 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-413046 [39] WPIX
DOC. NO. CPI: C2007-149572 [39]
TITLE: New tetrahydro-pyrrolo (1,2-b)isothiazole 1,1-dioxides useful for treating disorders associated with conditions of immune system, inflammation and transplantation e.g. asthma, Hashimoto's disease, multiple sclerosis, rheumatoid arthritis
DERWENT CLASS: A96; B02
INVENTOR: BAUMANN K
PATENT ASSIGNEE: (NOVS-C) NOVARTIS AG; (NOVS-C) NOVARTIS PHARMA GMBH
COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007039616	A1	20070412	(200739)*	EN	35[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 2007039616 A1 WO 2006-EP67017 20061004

PRIORITY APPLN. INFO: GB 2005-20378 20051006

AB WO 2007039616 A1 UPAB: 20070620

NOVELTY - Tetrahydro-pyrrolo (1,2-b)isothiazole 1,1-dioxides are new.

DETAILED DESCRIPTION - Tetrahydro-pyrrolo (1,2-b)isothiazole 1,1-dioxides of formula (I) are new. a=single or double bond;

R1=alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, aryl or heterocyclyl (all optionally substituted), H, OH, SH, SR5, cyano, halo or amino;

R2=H or optionally substituted cycloalkyl, aryl, or heterocyclyl; R3=H, COOR6, aminocarbonyl, or optionally substituted alkyl, alkenyl, alkynyl, aralkyl, alkoxy, cycloalkyloxy, aryloxy, or heterocycyloxy;

R4=H, halo, OH, SH, optionally substituted alkyl, alkenyl, alkynyl, alkoxy or alkylthio, or a silyl group such as trialkylsilyl or trialkylsilyloxy, e.g. tri(1-6C)alkylsilyl(oxy), N3, amino, or heterocyclyl comprising at least one nitrogen atom and is bound via that nitrogen atom to (I) or R4 is attached to the ring system by a double bond and is oxo; and

R5 and R6=alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl.

An INDEPENDENT CLAIM is included for a pharmaceutical combination comprising tetrahydro-pyrrolo (1,2-b)isothiazole 1,1-dioxides (I) in combination with at least one second drug substance. ACTIVITY - Antiinflammatory; Ophthalmological; Cardiant; Antiasthmatic; Respiratory-Gen.; Dermatological; Antiallergic and/or immunosuppressive; Neuroprotective; Osteopathic; Antithyroid; Thyromimetic; Antiarthritic; Antirheumatic; Antigout; Antipsoriatic; Gastrointestinal-Gen.; Antiulcer; Antibacterial; Antianemic; Antiallergic; Antidiabetic; Nephrotropic; Virucide; Vasotropic; CNS-Gen.; Antiseborrheic; Anti-HIV; Hepatotropic; Antiinfertility; Endocrine-Gen.; Gynecological; Immunomodulator; Cerebroprotective; Muscular-Gen.; Antimicrobial; Antimalarial; Fungicide.

MECHANISM OF ACTION - Lymphocyte function associated antigen 1 (LFA-1)/intercellular adhesion molecule (ICAM) inhibitor. Test details described. No specific results given.

USE - For the preparation of medicament for treating disorders mediated by interactions of LFA-1 (lymphocyte function associated antigen 1) with its ligands involved in cell adhesion, migration or activation (claimed); for treating disorders associated with inflammatory conditions e.g. (chronic) inflammatory disorders, e.g. bronchitis, cervicitis, conjunctivitis, esophagitis, myocarditis, pulmonary inflammation (alveolitis), airways, e.g. asthma, such as bronchial asthma, acute respiratory distress syndrome (ARDS), inflammatory skin disorders such as contact hypersensitivity, (allergic) contact dermatitis, atopic dermatitis, fibrotic disease (e.g. pulmonary fibrosis), encephalitis, inflammatory osteolysis, disorders associated with conditions of the immune system, such as autoimmune disorders e.g. including Graves' disease, Hashimoto's disease (chronic thyroiditis), multiple sclerosis, rheumatoid arthritis, arthritis, gout, osteoarthritis, scleroderma, lupus syndromes, systemic lupus erytomatosis, psoriasis, inflammatory bowel disease, including Crohn's disease, colitis, e.g. ulcerative colitis, sepsis, septic shock, autoimmune hemolytic anemia (AHA), autoantibody triggered urticaria, pemphigus, nephritis, glomerulonephritis, Goodpastur syndrom, ankylosing spondylitis, Reiter's syndrome, polymyositis, dermatomyositis, cytokine-mediated toxicity, interleukin-2 toxicity, alopecia, e.g. alopecia areata, hair growth, uveitis, lichen planus, bullous pemphigoid, myasthenia gravis, type I diabetes mellitus, immune-mediated infertility such as premature ovarian failure, polyglandular failure, hypothyroidism, pemphigus vulgaris, pemphigus l-oliaceus, paraneoplastic pemphigus, autoimmune hepatitis including that associated with hepatitis B virus (HBV) and hepatitis C virus (HCV), Addison's disease, autoimmune skin diseases, dermatitis herpetiformis, epidermolysis bullosa, linear IgA bullous dermatosis, epidermolysis bullosa acquisita chronic bullous disease of childhood, pernicious anemia, hemolytic anemia, vitiligo, type I, type Il and type III autoimmune polyglandular

syndromes, autoimmune hypoparathyroidism, autoimmune hypophysitis, autoimmune oophoritis, autoimmune orchitis, pemphigoid gestationis, cicatricial pemphigoid, mixed essential cryoglobulinemia, immune thrombocytopenic purpura, Good pasture's syndrome, autoimmune neutropenia, Eaton-Lambert myasthenic syndrome, stiff-man syndrome, encephalomyelitis, acute disseminated encephalomyelitis, Guillain-Barre syndrome, cerebellar degeneration, retinopathy, primary biliary sclerosis, sclerosing cholangitis autoimmune hepatitis, gluten-sensitive enteropathy, reactive arthritides, polymyositis/dermatomyositis, mixed connective tissue disease, Behcet's syndrome, polyarteritis nodosa allergic anguitis and granulomatosis (Churg-Strauss disease), polyangiitis overlap syndrome (hypersensitivity) vasculitis, Wegener's granulomatosis, temporal arteritis Kawasaki's disease, sarcoidosis, cryopathies, Celiac disease, disorders associated with skin and connective tissue conditions e.g. eczema, atopic dermatitis, (allergic) contact dermatitis, psoriasis, acne, dermatomyositis, Sjorgen's syndrome, Churg-Struass syndrome, sunburn, skin cancer urticaria, toxic epidermal necrolysis, age related skin conditions, cellulite, disorders associated with allergic conditions, e.g. including delayed-type hypersensitivity, allergic conjunctivitis, drug allergies, rhinitis, allergic rhinitis, vasculitis, contact dermatits, disorders associated with infectious disorders, e.g. with chronic infectious conditions, e.g. including bacterial disorders, otitis media, lyme disease, thyroiditis, viral disorders parasitic disorders, fungal disorders, malaria, e.g. malaria, anemia, sepsis, severe sepsis, septic shock, e.g. endotoxin-induced septic shock, exotoxin-induced toxic shock, infective (true septic) shock, septic shock caused by Gram-negative bacteria, pelvic inflammatory disease, AIDS, enteritis, pneumonia, meningitis, encephalitis, disorders associated with transplantation, e.g. including transplant rejection crisis and other disorders following transplantation, such as organ or tissue (xeno)transplant rejection, e.g. for the treatment of recipients of e.g. heart, lung, combined heart-lung, liver, kidney, pancreatic, skin, corneal transplants, graft versus host disease, such as following bone marrow transplantation, ischemic reperfusion injury.

ADVANTAGE - The compounds exhibits valuable pharmacological properties, e.g by mediating such as inhibiting the activity of LFA-1 (lymphocyte function associated antigen 1) interactions with its ligands, e.g. inhibiting the activity of LFA-1/ICAM-1 (intercellular adhesion molecule-1), LFA-1/ICAM-2, LFA-1/ICAM-3 and/or LFA-1/JAM-1 (junctional adhesion molecule 1) interactions e.g. LFA-1/ICAM-1 interaction, and thus mediating, e.g. inhibiting inflammation.

L87 ANSWER 19 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-412855 [39] WPIX
DOC. NO. CPI: C2007-149491 [39]
TITLE: Identifying a subject at risk of, or having, an indication associated with altered innate immunity by detecting the presence or absence of at least one nucleic acid variant in at least one Toll-like receptor (TLR) gene or its part
DERWENT CLASS: B04; D16
INVENTOR: NUYTINCK L
PATENT ASSIGNEE: (INNO-N) INNOGENETICS NV
COUNTRY COUNT: 115

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2007025989	A2	20070308	(200739)*	EN	186[4]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2007025989 A2		WO 2006-EP65821	20060830

PRIORITY APPLN. INFO: US 2005-717527P 20050915
EP 2005-108074 20050902

AB WO 2007025989 A2 UPAB: 20070620
NOVELTY - Identifying a subject at risk of, or having, an indication associated with altered innate immunity, comprises detecting the presence or absence of at least one nucleic acid variant in at least one Toll-like receptor (TLR) gene, or its part, where the presence of at least one nucleic acid variant identifies whether a subject is at risk or has an indication associated with an altered innate immunity.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are: (1) a diagnostic kit for identifying a subject at risk of, or having, an indication associated with altered innate immunity, comprising: (a) a means for detecting the presence or absence of one or more nucleic acid variants in at least one TLR gene; and (b) a means for determining, from the nucleic acid variant detected with the means of step (a), whether the subject is at risk of, or has, an indication associated with altered innate immunity;
(2) a method for selecting an appropriate treatment or therapeutic agent for a subject at risk of, or having, an indication associated with altered innate immunity;
(3) an isolated oligonucleotide consisting of 10 to 30 nucleotides for detecting the presence of one or more nucleic acid variants in at least on TLR gene; and
(4) a pair of primers suitable for amplifying a target TLR polynucleic acid.
USE - The method is useful in identifying a subject at risk of, or having, an indication associated with altered innate immunity or in selecting an appropriate treatment or therapeutic agent for a subject at risk of, or having, an indication associated with altered innate immunity (claimed).

L87 ANSWER 20 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-405068 [39] WPIX
DOC. NO. CPI: C2007-146849 [39]
TITLE: Decoction medicine for treating acute otitis media and its preparation
DERWENT CLASS: B04
INVENTOR: JIANG G; MING W
PATENT ASSIGNEE: (JIAN-I) JIANG G
COUNTRY COUNT: 1

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
CN 1895467	A	20070117	(200739)*	ZH	[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 1895467 A		CN 2006-10092020	20060610

PRIORITY APPLN. INFO: CN 2006-10092020 20060610
AB CN 1895467 A UPAB: 20070620

NOVELTY - A Chinese medicine in the form of decoction for treating acute tympanitis is prepared from 10 Chinese-medicinal materials including honeysuckle flower, red tuckahoe, coptis root, rhubarb, etc. Its preparing process is also disclosed.

L87 ANSWER 21 OF 1456 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2007-403528 [38] WPIX
DOC. NO. CPI: C2007-145847 [38]
TITLE: New growth factors, e.g. NsG29 or Ns31, useful for treating central nervous system disorders or for diseases related to testis, including male sterility, impotence, erectile dysfunction, or cancer
DERWENT CLASS: B04; D16
INVENTOR: BLOM N; BRUNAK S; GRONBORG M; JOHANSEN T E; KUSK P; PETERSEN T N; WAHLBERG L U
PATENT ASSIGNEE: (NSGE-N) NSGENE AS
COUNTRY COUNT: 111

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2006072601	A2	20060713	(200738)*	EN	124[23]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2006072601	A2	WO 2006-EP178	20060109

PRIORITY APPLN. INFO: DK 2005-1096 20050801
DK 2005-35 20050107
DK 2005-37 20050107
DK 2005-1097 20050801

AB WO 2006072601 A2 UPAB: 20070615
NOVELTY - An isolated polypeptide for medical use, comprising a sequence selected from:
(i) SEQ ID NOS: 3-6, 9-12, 15, 16, 18-20, 21, or 23, given in the specification;
(ii) a variant of the sequence selected from (i), where the variant has at least 70% sequence identity to the stated sequences; or (iii) a biologically active fragment of at least 50 contiguous amino acids of any of (i) or (ii), is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) an isolated nucleic acid molecule, for medical use, comprising a nucleotide sequence selected from: (i) a nucleotide sequence coding for a polypeptide having the amino acid sequence selected from SEQ ID NOS: 3-6, 9-12, 15, 16, 18-20, 21, or 23;
(ii) a nucleotide sequence coding for a sequence variant of the amino acid sequence selected from SEQ ID NOS: 3-6, 9-12, 15, 16, 18-20, 21, or 23, where the variant has at least 70% sequence identity to the stated sequences;
(iii) a nucleotide sequence coding for a biologically active fragment of at least 50 contiguous amino acids of any of (i) or (ii); (iv) a nucleotide sequence selected from SEQ ID NOS: 2, 8, 14, 17, or 22, given in the specification;
(v) a nucleotide sequence having at least 70% sequence identity to a coding sequence selected from the coding sequence of SEQ ID NO: 2, 8, 14, 17, or 22;

(vi) a nucleic acid sequence of at least 150 contiguous nucleotides of a coding sequence selected from the coding sequence of SEQ ID NOS: 2, 8, 14, 17, or 22;
(vii) the complement of a nucleic acid capable of hybridizing with a nucleic acid molecule having the sequence of the coding sequence of SEQ ID NOS: 2, 8, 14, 17, or 22 under conditions of high stringency; or (viii) the nucleic acid sequence of the complement of any of (i) - (vii);
(2) a vector comprising the nucleic acid molecule; (3) an isolated host cell transfected or transduced with the vector;
(4) a packaging cell line capable of producing an infective virus particle, the virus particle comprising a Retroviridae derived genome comprising a 5' retroviral long terminal repeat (LTR), a tRNA binding site, a packaging signal, a promoter operably linked to a polynucleotide sequence encoding the new polypeptide, an origin of second strand DNA synthesis, and a 3' retroviral LTR; (5) an implantable biocompatible cell device comprising: (i) a semipermeable membrane permitting the diffusion of the new protein and/or a virus vector; and
(ii) a composition of cells or a packaging cell line of (4); (6) a pharmaceutical composition comprising the polypeptide, or the isolated nucleic acid, the expression vector, or a composition of host cells, or a packaging cell line, or an implantable biocompatible cell device, and a pharmaceutical carrier; (7) a method of treating a pathological condition in a subject; (8) a method of expanding a composition of mammalian cells; (9) a method of differentiating a composition of mammalian cells; (10) an antibody capable of binding to the new polypeptide for medical use;
(11) an immunoconjugate comprising the antibody and a conjugate selected from:
(i) a cytotoxic agent such as a chemotherapeutic agent, a toxin, or a radioactive isotope;
(ii) a member of a specific binding pair, such as avidin or streptavidin or an antigen; and
(iii) an enzyme capable of producing a detectable product; and (12) a method of preventing apoptosis in a neuronal cell. ACTIVITY - CNS-Gen; Cerebroprotective; Antiparkinsonian; Nootropic; Neuroprotective; Anticonvulsant; Metabolic; Antidiabetic; Nephrotropic; Analgesic; Ophthalmological; Auditory; Cytostatic; Antiinfertility; Vasotropic; Antialcoholic; Antimicrobial; Inotropic; Hypertensive. No biological data given.
MECHANISM OF ACTION - Gene therapy; Cell therapy; Apoptosis inhibitor.
USE - The polypeptide, isolated nucleic acid sequence, expression vector, composition of host cells, packaging cell line, or implantable biocompatible cell device is useful manufacturing a medicament for the treatment of a disease, disorder, or damage associated with the nervous system.
The disease, disorder, or damage involves neuronal apoptosis; injury to the brain, brain stem, the spinal cord, and/or peripheral nerves, including stroke (cerebrovascular ischemia), traumatic brain injury, spinal cord injury, diffuse axonal injury, epilepsy, neuropathy, peripheral neuropathy and associated pain and other symptoms, and where the neurodegenerative disease is thalamic pain; degeneration of neurons and their processes in the brain, brain stem, the spinal cord, and/or the peripheral nerves, including Parkinson's Disease, Alzheimer's Disease, senile dementia, Huntington's Disease, amyotrophic lateral sclerosis (motor neurone disease), neuronal injury associated with multiple sclerosis, and associated symptoms; dysfunction and/or loss of neurons in the brain, brain stem, the spinal cord, and/or peripheral nerves, including metabolic diseases, nutritional deficiency, toxic injury, malignancy, and/or genetic or idiopathic conditions including diabetes, renal dysfunction, alcoholism, chemotherapy, chemical agents, drug abuse, vitamin deficiency, and infection, where the disorder is essential tremor, or where the disease is peripheral neuropathy and associated pain; is associated with the cerebellum, including sensory ataxia, multiple sclerosis, neurodegenerative spinocerebellar disorders, hereditary ataxia, cerebellar

atrophies (such as olivopentocerebellar atrophy (OPCA), Shy-Drager Syndrome (multiple systems atrophy), and alcoholism; degeneration or sclerosis of glia such as oligodendrocytes, astrocytes and Schwanri cells in the brain, brain stem, the spinal cord, and the peripheral nerves, including but not limited to multiple sclerosis, optic neuritis, cerebral sclerosis, post-infectious encephalomyelitis, and epilepsy and associated symptoms; the retina, photoreceptors, and associated nerves including retinitis pigmentosa, macular degeneration, glaucoma, diabetic retinopathy, and associated symptoms; the sensory epithelium and associated ganglia of the vestibuloacoustic complex including noise-induced hearing loss, deafness, tinnitus, otitis , labyrintitis, hereditary and cochleovestibular atrophies, Meniere disease (inner ear disease), and associated symptoms; and the treatment of a disease related to testis, including male sterility (male infertility), impotence, erectile dysfunction, cancer, and germ cell tumors (all claimed).

L98 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2004:430739 CAPLUS Full-text
DOCUMENT NUMBER: 140:429029
TITLE: Otoprotective compositions that treat ototoxic side effects of aminoglycoside antibiotics and platinum-containing antineoplastic agents
INVENTOR(S): Currie, Mark G.; Heefner, Donald L. ; Rubin, Paul; Zepp, Charles M.
PATENT ASSIGNEE(S): Sepracor, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004043447	A2	20040527	WO 2003-US36269		20031113
WO 2004043447	A3	20050127			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2003299560	A1	20040603	AU 2003-299560		20031113
US 2005101534	A1	20050512	US 2003-712849		20031113
PRIORITY APPLN. INFO.:			US 2002-425878P	P	20021113
			WO 2003-US36269	W	20031113

OTHER SOURCE(S): MARPAT 140:429029

L98 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1980:15423 CAPLUS Full-text
DOCUMENT NUMBER: 92:15423
TITLE: False precursors of melanin as selective melanoma seekers
AUTHOR(S): Dencker, L.; Larsson, B.; Olander, K.; Ullberg, S.; Yokota, M.
CORPORATE SOURCE: Biomed. Cent., Univ. Uppsala, Uppsala, Swed.
SOURCE: British Journal of Cancer (1979), 39(4), 449-52
CODEN: BJCAAI; ISSN: 0007-0920
DOCUMENT TYPE: Journal
LANGUAGE: English

L98 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1976:29503 CAPLUS Full-text
DOCUMENT NUMBER: 84:29503
TITLE: Interrelations between athyreotic and copper-deficient states in rats
AUTHOR(S): Oliver, Jack W.
CORPORATE SOURCE: Coll. Vet. Med., Ohio State Univ., Columbus, OH, USA
SOURCE: American Journal of Veterinary Research (1975), 36(11), 1649-53
CODEN: AJVRAH; ISSN: 0002-9645
DOCUMENT TYPE: Journal
LANGUAGE: English

L98 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1966:415571 CAPLUS Full-text
DOCUMENT NUMBER: 65:15571
ORIGINAL REFERENCE NO.: 65:2921c-e
TITLE: Effect of a nucleic acid and its antimetabolites on induction of flowering in winter cereals
AUTHOR(S): Suge, Hiroshi; Yamada, Noboru
CORPORATE SOURCE: Natl. Inst. Agr. Sci., Konosu, Japan
SOURCE: Nippon Sakumotsu Gakkai Kiji (1965), 33(4), 324-9
CODEN: NISAAJ; ISSN: 0011-1848
DOCUMENT TYPE: Journal
LANGUAGE: English

L98 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1960:30379 CAPLUS Full-text
DOCUMENT NUMBER: 54:30379
ORIGINAL REFERENCE NO.: 54:5965g-i
TITLE: Thyroid, parathyroid, and calcium salts of the endolymphatic sac in thiouracil-treated larvae of Bufo bufo bufo
AUTHOR(S): Guardabassi, Antonietta
CORPORATE SOURCE: Univ. Turin
SOURCE: Arch. ital. anat. e embriol. (1959), 64, 105-27
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

L98 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1946:5568 CAPLUS Full-text
DOCUMENT NUMBER: 40:5568
ORIGINAL REFERENCE NO.: 40:955a-d
TITLE: Thiouracil in goiter
AUTHOR(S): Cookson, Harold
CORPORATE SOURCE: Cornelia Hosp., Poole, UK
SOURCE: Lancet (1945), 249, 485-9
CODEN: LANCAO; ISSN: 0140-6736

DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

L98 ANSWER 7 OF 27 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2006432588 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 16855499
TITLE: When is enophthalmos "significant"?.
AUTHOR: Koo Lily; Hatton Mark P; Rubin Peter A D
CORPORATE SOURCE: Ophthalmic Plastics, Orbital, and Aesthetic Surgery, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA.
SOURCE: Ophthalmic plastic and reconstructive surgery, (2006 Jul-Aug) Vol. 22, No. 4, pp. 274-7.
Journal code: 8508431. ISSN: 0740-9303.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200608
ENTRY DATE: Entered STN: 21 Jul 2006
Last Updated on STN: 17 Aug 2006
Entered Medline: 16 Aug 2006

L98 ANSWER 8 OF 27 MEDLINE on STN DUPLICATE 2
ACCESSION NUMBER: 2005110437 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 15558295
TITLE: The clinicopathological spectrum of benign peripunctal tumours.
AUTHOR: Rumelt Shimon; Pe'er Jacob; Rubin Peter A D
CORPORATE SOURCE: Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.
SOURCE: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, (2005 Feb) Vol. 243, No. 2, pp. 113-9. Electronic Publication: 2004-11-19.
Journal code: 8205248. ISSN: 0721-832X.
PUB. COUNTRY: Germany: Germany, Federal Republic of
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200504
ENTRY DATE: Entered STN: 3 Mar 2005
Last Updated on STN: 26 Apr 2005
Entered Medline: 25 Apr 2005

L98 ANSWER 9 OF 27 MEDLINE on STN DUPLICATE 4
ACCESSION NUMBER: 2003124162 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 12623823
TITLE: Bilateral cavernous sinus thromboses and intraorbital abscesses secondary to Streptococcus milleri.
AUTHOR: Watkins Lynnette M; Pasternack Mark S; Banks Michelle; Kousoubris Philip; Rubin Peter A D
CORPORATE SOURCE: Ophthalmic Plastic, Orbital, Reconstructive and Cosmetic Surgery Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA.
SOURCE: Ophthalmology, (2003 Mar) Vol. 110, No. 3, pp. 569-74.
Journal code: 7802443. ISSN: 0161-6420.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)

Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 18 Mar 2003
Last Updated on STN: 25 Mar 2003
Entered Medline: 24 Mar 2003

L98 ANSWER 10 OF 27 MEDLINE on STN DUPLICATE 5
ACCESSION NUMBER: 2001315737 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 11388382
TITLE: Orbital fractures in children.
AUTHOR: Hatton M P; Watkins L M; Rubin P A
CORPORATE SOURCE: Massachusetts Eye and Ear Infirmary, Boston, Massachusetts 02114, USA.
SOURCE: Ophthalmic plastic and reconstructive surgery, (2001 May) Vol. 17, No. 3, pp. 174-9.
Journal code: 8508431. ISSN: 0740-9303.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200110
ENTRY DATE: Entered STN: 8 Oct 2001
Last Updated on STN: 8 Oct 2001
Entered Medline: 4 Oct 2001

L98 ANSWER 11 OF 27 MEDLINE on STN DUPLICATE 6
ACCESSION NUMBER: 1998254230 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 9593398
TITLE: Enhancement of the cosmetic and functional outcome of enucleation with the conical orbital implant.
AUTHOR: Rubin P A; Popham J; Rumelt S; Remulla H; Bilyk J R; Holds J; Mannor G; Maus M; Patrinely J R
CORPORATE SOURCE: Ophthalmic Plastics, Orbital, and Cosmetic Eyelid Surgery, Massachusetts Eye and Ear Infirmary, Boston 02114, USA.
SOURCE: Ophthalmology, (1998 May) Vol. 105, No. 5, pp. 919-25.
Journal code: 7802443. ISSN: 0161-6420.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199805
ENTRY DATE: Entered STN: 29 May 1998
Last Updated on STN: 29 May 1998
Entered Medline: 21 May 1998

L98 ANSWER 12 OF 27 MEDLINE on STN DUPLICATE 7
ACCESSION NUMBER: 97452852 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 9307642
TITLE: Orbital venous anomalies demonstrated by spiral computed tomography.
AUTHOR: Rubin P A; Remulla H D
CORPORATE SOURCE: Department of Ophthalmology Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA.
SOURCE: Ophthalmology, (1997 Sep) Vol. 104, No. 9, pp. 1463-70.
Journal code: 7802443. ISSN: 0161-6420.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CASE REPORTS)
Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199710
ENTRY DATE: Entered STN: 13 Oct 1997
Last Updated on STN: 13 Oct 1997
Entered Medline: 2 Oct 1997

L98 ANSWER 13 OF 27 MEDLINE on STN
ACCESSION NUMBER: 2007436310 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 17648453
TITLE: Surgery for the Relief or Correction of Disease of the Ear of the Dog and Cat.
AUTHOR: Zepp C P
SOURCE: Canadian journal of comparative medicine and veterinary science, (1950 Jan) Vol. 14, No. 1, pp. 19-21.
Journal code: 0151757. ISSN: 0316-5957.
PUB. COUNTRY: Canada
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: NONMEDLINE; PUBMED-NOT-MEDLINE
ENTRY MONTH: 200707
ENTRY DATE: Entered STN: 28 Jul 2007
Last Updated on STN: 28 Jul 2007
Entered Medline: 27 Jul 2007

L98 ANSWER 14 OF 27 MEDLINE on STN
ACCESSION NUMBER: 2007436309 MEDLINE Full-text
DOCUMENT NUMBER: PubMed ID: 17648452
TITLE: Ear Diseases of the Dog and Cat.
AUTHOR: Zepp C P
SOURCE: Canadian journal of comparative medicine and veterinary science, (1950 Jan) Vol. 14, No. 1, pp. 15-9.
Journal code: 0151757. ISSN: 0316-5957.
PUB. COUNTRY: Canada
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: NONMEDLINE; PUBMED-NOT-MEDLINE
ENTRY MONTH: 200707
ENTRY DATE: Entered STN: 28 Jul 2007
Last Updated on STN: 28 Jul 2007
Entered Medline: 27 Jul 2007

L98 ANSWER 15 OF 27 EMBASE
ACCESSION NUMBER: 2006346540 EMBASE Full-text
TITLE: Role of inflammation in orbital cellulitis.
AUTHOR: Kloek C.E.; Rubin P.A.D.
CORPORATE SOURCE: Dr. C.E. Kloek, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, United States
SOURCE: International Ophthalmology Clinics, (2006) Vol. 46, No. 2, pp. 57-68. .
Refs: 41
ISSN: 0020-8167 CODEN: IOPCAV
PUBLISHER IDENT.: 00004397200604620000007
COUNTRY: United States
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 012 Ophthalmology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English

SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 18 Aug 2006
Last Updated on STN: 18 Aug 2006

L98 ANSWER 16 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2003045694 EMBASE Full-text
TITLE: Medial rectus muscle injuries associated with functional endoscopic sinus surgery: Characterization and management.
AUTHOR: Huang C.M.; Meyer D.R.; Patrinely J.R.; Soparkar C.N.S.; Dailey R.A.; Maus M.; Rubin P.A.D.; Patrick Yeatts R.; Bersani T.A.; Karesh J.W.; Harrison A.R.; Shovlin J.P.
CORPORATE SOURCE: Dr. D.R. Meyer, Lions Eye Institute, Albany Medical Center, 35 Hackett Blvd., Albany, NY 12208, United States. meyerd@mail.amc.edu
SOURCE: Ophthalmic Plastic and Reconstructive Surgery, (2003) Vol. 19, No. 1, pp. 25-37. .
Refs: 37
ISSN: 0740-9303 CODEN: OPRSEU
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 011 Otorhinolaryngology
012 Ophthalmology
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 7 Feb 2003
Last Updated on STN: 7 Feb 2003

L98 ANSWER 17 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 93307672 EMBASE Full-text
DOCUMENT NUMBER: 1993307672
TITLE: On the intonation of sinusoidal sentences: Contour and pitch height.
AUTHOR: Remez R.E.; Rubin P.E.
CORPORATE SOURCE: Department of Psychology, Barnard College, 3009 Broadway,New York, NY 10027-6598, United States
SOURCE: Journal of the Acoustical Society of America, (1993) Vol. 94, No. 4, pp. 1983-1988. .
ISSN: 0001-4966 CODEN: JASMAN
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 011 Otorhinolaryngology
027 Biophysics, Bioengineering and Medical Instrumentation
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 14 Nov 1993
Last Updated on STN: 14 Nov 1993

L98 ANSWER 18 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 91026329 EMBASE Full-text
DOCUMENT NUMBER: 1991026329
TITLE: A request for an abortion.
AUTHOR: Walker A.; Marsden S.; Rubin P.
CORPORATE SOURCE: University Hospital, Nottingham, United Kingdom
SOURCE: Practitioner, (1990) Vol. 234, No. 1497, pp. 1013-1016. .
ISSN: 0032-6518 CODEN: PRACAK

COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 010 Obstetrics and Gynecology
011 Otorhinolaryngology
037 Drug Literature Index
038 Adverse Reactions Titles
LANGUAGE: English
ENTRY DATE: Entered STN: 16 Dec 1991
Last Updated on STN: 16 Dec 1991

L98 ANSWER 19 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 90144580 EMBASE Full-text
DOCUMENT NUMBER: 1990144580
TITLE: Childhood otalgia: Acute otitis media. 1. Antibiotics not necessary in most cases: Editorial comment.
AUTHOR: Rubin P.C.
CORPORATE SOURCE: University of Nottingham, Nottingham, United Kingdom
SOURCE: British Medical Journal, (1990) Vol. 300, No. 6730, pp. 1005. .
ISSN: 0959-8146 CODEN: BMJOAE
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Note
FILE SEGMENT: 007 Pediatrics and Pediatric Surgery
011 Otorhinolaryngology
037 Drug Literature Index
LANGUAGE: English
ENTRY DATE: Entered STN: 13 Dec 1991
Last Updated on STN: 13 Dec 1991

L98 ANSWER 20 OF 27 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 78180793 EMBASE Full-text
DOCUMENT NUMBER: 1978180793
TITLE: Mosaic trisomy 9: Two additional cases.
AUTHOR: Tropp M.R.; Currie M.
CORPORATE SOURCE: Pathol. Dept., Roy. Child. Hosp., Melbourne, Australia
SOURCE: Human Genetics, (1977) Vol. 38, No. 2, pp. 131-135. .
CODEN: HUGEDQ
COUNTRY: Germany
DOCUMENT TYPE: Journal
FILE SEGMENT: 022 Human Genetics
007 Pediatrics and Pediatric Surgery
LANGUAGE: English

L98 ANSWER 21 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2006-569520 [58] WPIX
CROSS REFERENCE: 2005-173214
DOC. NO. CPI: C2006-177026 [58]
TITLE: Novel purified polypeptide that activates guanylate cyclase C receptor, useful for treating diseases e.g. gastrointestinal disorders, obesity or congestive heart failure
DERWENT CLASS: B04
INVENTOR: CURRIE M G; KURTZ C; MAHAJAN-MIKLOS S; SUN L J
PATENT ASSIGNEE: (MICR-N) MICROBIA INC
COUNTRY COUNT: 111

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2006086653	A2	20060817	(200658)*	EN	409[3]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2006086653	A2	WO 2006-US4768	20060208

PRIORITY APPLN. INFO: US 2005-54072 20050208

L98 ANSWER 22 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2005-582766 [59] WPIX
DOC. NO. CPI: C2005-175823 [59]
TITLE: Use of composition comprising chymotrypsin inhibitor in the treatment of patient suffering from or at risk for congestive heart failure, prostatic hyperplasia, gastrointestinal disorder; obesity; and for decreasing gastrointestinal pain
DERWENT CLASS: B05
INVENTOR: CURRIE M G
PATENT ASSIGNEE: (MICR-N) MICROBIA INC
COUNTRY COUNT: 106

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2005074575	A2	20050818	(200559)*	EN	207[5]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2005074575	A2	WO 2005-US2941	20050131

PRIORITY APPLN. INFO: US 2004-540675P 20040130

L98 ANSWER 23 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-604332 [58] WPIX
CROSS REFERENCE: 2005-639160
DOC. NO. CPI: C2004-218947; C2006-063571 [58] [20]
TITLE: Novel purified peptide capable of activating the guanylate cyclase C receptor, useful for treating obesity, congestive heart failure and benign prostatic hyperplasia
DERWENT CLASS: B04; B05; D16
INVENTOR: CURRIE M G; MAHAJAN M S; MAHAJAN-MIKLOS S; MILNE G T; MILNE T G; NORMAN T; THEA N; CURRIE M
PATENT ASSIGNEE: (CURR-I) CURRIE M G; (MAHA-I) MAHAJAN-MIKLOS S; (MICR-N) MICROBIA INC
COUNTRY COUNT: 107

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2004069165	A2	20040819	(200458)*	EN	93[10]	
US 20040266989	A1	20041230	(200503)	EN		

US 20050020811	A1	20050127	(200509)	EN	
AU 2004210161	A1	20040819	(200562)	EN	
EP 1594517	A2	20051116	(200575)	EN	
BR 2004007071	A	20060124	(200611)	PT	
NO 2005003864	A	20051026	(200622)	NO	1[0]
MX 2005008097	A1	20060201	(200643)	ES	
JP 2006516631	W	20060706	(200645)	JA	63
KR 2005106404	A	20051109	(200667)	KO	
CN 1795007	A	20060628	(200672)	ZH	
ZA 2005006714	A	20061129	(200703)	EN	106
EP 1594517	B1	20070620	(200741)	EN	
IN 2005DN03394	P1	20070601	(200748)	EN	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION DATE
WO 2004069165	A2	WO 2004-US2390 20040128
US 20040266989	A1 Provisional	US 2003-443098P 20030128
US 20050020811	A1 Provisional	US 2003-443098P 20030128
US 20040266989	A1 Provisional	US 2003-471288P 20030515
US 20050020811	A1 Provisional	US 2003-471288P 20030515
US 20040266989	A1 Provisional	US 2003-519460P 20031112
US 20050020811	A1 Provisional	US 2003-519460P 20031112
AU 2004210161	A1	AU 2004-210161 20040128
BR 2004007071	A	BR 2004-7071 20040128
CN 1795007	A	CN 2004-80008533 20040128
EP 1594517	A2	EP 2004-706011 20040128
EP 1594517	B1	EP 2004-706011 20040128
US 20040266989	A1	US 2004-766735 20040128
US 20050020811	A1 CIP of	US 2004-766735 20040128
EP 1594517	A2	WO 2004-US2390 20040128
BR 2004007071	A	WO 2004-US2390 20040128
MX 2005008097	A1	WO 2004-US2390 20040128
JP 2006516631	W	WO 2004-US2390 20040128
KR 2005106404	A	WO 2004-US2390 20040128
EP 1594517	B1	WO 2004-US2390 20040128
US 20050020811	A1	US 2004-796719 20040309
ZA 2005006714	A	ZA 2005-6714 20040128
KR 2005106404	A	KR 2005-713966 20050728
MX 2005008097	A1	MX 2005-8097 20050728
NO 2005003864	A	NO 2005-3864 20050818
JP 2006516631	W	JP 2006-503109 20040128
IN 2005003394	P1	WO 2004-US2390 20040128
IN 2005003394	P1	IN 2005-DN3394 20050801

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
AU 2004210161	A1	Based on	WO 2004069165	A
EP 1594517	A2	Based on	WO 2004069165	A
BR 2004007071	A	Based on	WO 2004069165	A
MX 2005008097	A1	Based on	WO 2004069165	A
JP 2006516631	W	Based on	WO 2004069165	A
KR 2005106404	A	Based on	WO 2004069165	A
EP 1594517	B1	Based on	WO 2004069165	A

PRIORITY APPLN. INFO: US 2003-519460P 20031112
US 2003-443098P 20030128

US 2003-471288P 20030515
US 2004-766735 20040128
US 2004-796719 20040309

L98 ANSWER 24 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-579216 [54] WPIX
CROSS REFERENCE: 2000-587227; 2001-565399
DOC. NO. CPI: C2000-172404 [54]
TITLE: Method for treating neuropathic pain, including central and peripheral neuropathy, and tinnitus comprises administration of R(-)-ketoprofen
DERWENT CLASS: B05
INVENTOR: JERUSSI T P; RUBIN P D
PATENT ASSIGNEE: (SEPR-N) SEPRACOR INC
COUNTRY COUNT: 89

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2000051595	A1	20000908	(200054)*	EN	26[0]	
AU 2000037111	A	20000921	(200065)	EN		
EP 1156794	A1	20011128	(200201)	EN		
US 6362227	B1	20020326	(200226)	EN		
US 20020147238	A1	20021010	(200269)	EN		
JP 2003520193	W	20030702	(200352)	JA	31	
US 6620851	B2	20030916	(200362)	EN		
US 20040019111	A1	20040129	(200413)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000051595	A1	WO 2000-US5170	20000301
US 6362227	B1 Provisional	US 1999-122382P	19990302
US 20020147238	A1 Provisional	US 1999-122382P	19990302
US 6620851	B2 Provisional	US 1999-122382P	19990302
US 20040019111	A1 Provisional	US 1999-122382P	19990302
US 6362227	B1	US 2000-507470	20000222
US 20020147238	A1 Div Ex	US 2000-507470	20000222
US 6620851	B2 Div Ex	US 2000-507470	20000222
US 20040019111	A1 Div Ex	US 2000-507470	20000222
AU 2000037111	A	AU 2000-37111	20000301
EP 1156794	A1	EP 2000-915921	20000301
JP 2003520193	W	JP 2000-602063	20000301
EP 1156794	A1	WO 2000-US5170	20000301
JP 2003520193	W	WO 2000-US5170	20000301
US 20020147238	A1	US 2002-62766	20020205
US 6620851	B2	US 2002-62766	20020205
US 20040019111	A1 Div Ex	US 2002-62766	20020205
US 20040019111	A1	US 2003-620704	20030717

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 20020147238	A1 Div ex	US 6362227 B
US 6620851	B2 Div ex	US 6362227 B
US 20040019111	A1 Div ex	US 6362227 B
US 20040019111	A1 Div ex	US 6620851 B

AU 2000037111 A	Based on	WO 2000051595 A
EP 1156794 A1	Based on	WO 2000051595 A
JP 2003520193 W	Based on	WO 2000051595 A

PRIORITY APPLN. INFO: US 2000-507470 20000222
US 1999-122382P 19990302
US 2002-62766 20020205
US 2003-620704 20030717

L98 ANSWER 25 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 2000-431259 [37] WPIX
CROSS REFERENCE: 1999-095304; 1999-095313; 2001-181513; 2002-453150
DOC. NO. CPI: C2000-131036 [37]
TITLE: New quinoline-indole compounds, useful for treating bacterial infections, particularly antibiotic resistant infections, or for inhibiting microbial growth in tissue culture
DERWENT CLASS: B02; B04; C02; D16
INVENTOR: CUNY G D; HAUSKE J R; HEEFNER D L; HOEMANN M Z; KUMARAVEL G; MELIKIAN-BADALIAN A; ROSSI R F; XIE R L
PATENT ASSIGNEE: (SEPR-N) SEPRACOR INC
COUNTRY COUNT: 88

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2000034265	A2	20000615	(200037)*	EN	154[0]	
US 6103905	A	20000815	(200041)	EN		
AU 2000019335	A	20000626	(200045)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2000034265	A2	WO 1999-US28744	19991203
US 6103905	A CIP of	US 1997-878781	19970619
US 6103905	A CIP of	US 1998-45051	19980319
US 6103905	A CIP of	US 1998-99640	19980618
US 6103905	A	US 1998-213385	19981211
AU 2000019335	A	AU 2000-19335	19991203

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 2000019335	A	Based on	WO 2000034265 A

PRIORITY APPLN. INFO: US 1998-213385 19981211
US 1997-878781 19970619
US 1998-45051 19980319
US 1998-99640 19980618

L98 ANSWER 26 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 1999-095313 [08] WPIX
CROSS REFERENCE: 1999-095304; 2000-431259; 2001-181513; 2002-453150
DOC. NO. CPI: C1999-028059 [08]
TITLE: New isoquinoline-indole derivatives - used for treating bacterial infection and are active against Gram positive and Gram negative bacteria, including multiply resistant

strains
DERWENT CLASS: B05
INVENTOR: CUNY G D; HAUSKE J R; HEEFNER D L; HOEMANN M Z; KUMARAVEL G; MELIKIAN-BADALIAN A; ROSSI R F
PATENT ASSIGNEE: (SEPR-N) SEPRACOR INC
COUNTRY COUNT: 80

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9857952	A1	19981223	(199908)*	EN	137[0]	
AU 9882586	A	19990104	(199921)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9857952 A1		WO 1998-US12706	19980618
AU 9882586 A		AU 1998-82586	19980618

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9882586 A	Based on	WO 9857952 A

PRIORITY APPLN. INFO: US 1997-878781 19970619

L98 ANSWER 27 OF 27 WPIX COPYRIGHT 2007 THE THOMSON CORP on STN
ACCESSION NUMBER: 1999-095304 [08] WPIX
CROSS REFERENCE: 1999-095313; 2000-431259; 2001-181513; 2002-453150
DOC. NO. CPI: C1999-028050 [08]
TITLE: New 2-(Indol-3-yl)quinoline compounds - active against Gram positive and Gram negative bacteria, including multiply resistant strains
DERWENT CLASS: B02; B05
INVENTOR: CUNY G D; HAUSKE J R; HEEFNER D L; HOEMANN M Z; KUMARAVEL G; MELIKIAN-BADALIAN A; ROSSI R F
PATENT ASSIGNEE: (SEPR-N) SEPRACOR INC
COUNTRY COUNT: 81

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 9857931	A2	19981223	(199908)*	EN	145[0]	
AU 9879797	A	19990104	(199921)	EN		
NO 9906269	A	20000216	(200020)	NO		
EP 991623	A2	20000412	(200023)	EN		
CZ 9904608	A3	20000816	(200048)	CS		
US 6207679	B1	20010327	(200119)	EN		
HU 2000003364	A2	20010628	(200143)	HU		
KR 2001014030	A	20010226	(200154)	KO		
JP 2002505689	W	20020219	(200216)	JA	189	
AU 757059	B	20030130	(200319)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 9857931 A2	WO 1998-US12762 19980618
US 6207679 B1 CIP of	US 1997-878781 19970619
US 6207679 B1	US 1998-45051 19980319
AU 9879797 A	AU 1998-79797 19980618
AU 757059 B	AU 1998-79797 19980618
EP 991623 A2	EP 1998-930396 19980618
NO 9906269 A	WO 1998-US12762 19980618
EP 991623 A2	WO 1998-US12762 19980618
CZ 9904608 A3	WO 1998-US12762 19980618
HU 2000003364 A2	WO 1998-US12762 19980618
JP 2002505689 W	WO 1998-US12762 19980618
CZ 9904608 A3	CZ 1999-4608 19980618
JP 2002505689 W	JP 1999-504835 19980618
NO 9906269 A	NO 1999-6269 19991217
KR 2001014030 A	KR 1999-712059 19991220
HU 2000003364 A2	HU 2000-3364 19980618

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 757059 B	Previous Publ	AU 9879797 A
AU 9879797 A	Based on	WO 9857931 A
EP 991623 A2	Based on	WO 9857931 A
CZ 9904608 A3	Based on	WO 9857931 A
HU 2000003364 A2	Based on	WO 9857931 A
JP 2002505689 W	Based on	WO 9857931 A
AU 757059 B	Based on	WO 9857931 A

PRIORITY APPLN. INFO: US 1998-45051 19980319
US 1997-878781 19970619

```
=> fil caplus medline biosis embase
FILE 'CAPLUS' ENTERED AT 13:43:33 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 13:43:33 ON 20 AUG 2007

FILE 'BIOSIS' ENTERED AT 13:43:33 ON 20 AUG 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:43:33 ON 20 AUG 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> d que nos
L105      54949 SEA HEARING (2A) LOSS
L107      17784 SEA PYRIMIDINE## (3A) DERIV?
L108          2 SEA L105 AND L107


=> d ibib ab ct 1-2 l108

L108 ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:438159  CAPLUS  Full-text
DOCUMENT NUMBER:          146:441811
TITLE:                    Preparation of novel pyrimidine-2,4-diamine
```

derivatives and their use as modulators of small-conductance calcium-activated potassium channels

INVENTOR(S): Soerensen, Ulrik Svane; Eriksen, Birgitte L.; Teuber, Lene; Peters, Dan; Stroebaek, Dorte; Johansen, Tina Holm; Christophersen, Palle

PATENT ASSIGNEE(S): Neurosearch A/S, Den.

SOURCE: PCT Int. Appl., 29pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007042571	A1	20070419	WO 2006-EP67387	20061013

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: DK 2005-1439 A 20051014
US 2005-726508P P 20051014

OTHER SOURCE(S): MARPAT 146:441811

AB This invention relates to novel pyrimidine-2,4-diamine derivs. I [R1 = (CH2)vR5 (wherein v = 0 or 1; R5 = (un)substituted aryl); R11, R111 = H or (un)substituted alkyl; or R11 together with R111 form (CH2)p (p = 3-5); or R11 forms a (CH2)q bridge to an ortho position of the aryl group of R1 (q = 2-4) and R111 = H or (un)substituted alkyl; R2 = (CH2)wR6 (w = 0-1; R6 = (un)substituted aryl); R22, R222 = H or (un)substituted alkyl; or R22 together with R222 form (CH2)s (s = 3-5); or R22 forms a (CH2)t bridge to an ortho position of the aryl group of R2 (t = 2-4) and R222 = H or (un)substituted alkyl; R3, R4 = H, halo, CF3, etc.], useful as modulators of small-conductance calcium-activated potassium channels (SK channels). Fourteen compds. I were prepared Thus, reacting 2,4-dichloropyrimidine with 3,4-difluorobenzylamine afforded N2,N4-bis(3,4-difluorobenzyl)pyrimidine- 2,4-diamine. In other aspects the invention relates to the use of the compds. I in a method for therapy and to pharmaceutical compns. comprising the compds. I.

CT Blood vessel, disease
CT Amnesia
CT Nervous system, disease
CT Mental and behavioral disorders
CT Mental and behavioral disorders
CT Bladder, disease
CT Bladder, disease
CT Potassium channel
CT Drug delivery systems
CT Embolism
CT Ischemia
CT Lung, disease
CT Inflammation
CT Intestine, disease
CT Intestine, disease

CT Mental and behavioral disorders
CT Mental and behavioral disorders
CT Gastrointestinal motility
CT Gastrointestinal motility
CT Digestive tract, disease
CT Intestine, disease
CT Sexual disorders
CT Bladder, disease
CT Pain
CT Intestine, disease
CT Artery, disease
CT Intestine, disease
CT Brain, disease
CT Memory disorders
CT Headache
CT Mental and behavioral disorders
CT Nerve, disease
CT Neuromuscular diseases
CT Muscular dystrophy
CT Muscular dystrophy
CT Pain
CT Diabetes mellitus
CT Bladder, disease
CT Epilepsy
CT Drug delivery systems
CT Kidney, disease
CT Parturition disorders
CT Aging, animal
CT Alopecia
CT Alzheimer's disease
CT Analgesics
CT Angina pectoris
CT Anti-Alzheimer's agents
CT Anti-inflammatory agents
CT Anti-ischemic agents
CT Antianginal agents
CT Antiarrhythmics
CT Antiasthmatics
CT Anticonvulsants
CT Antidepressants
CT Antidiabetic agents
CT Antidiarrheals
CT Antifibrotic agents
CT Antihypertensives
CT Antimigraine agents
CT Antiparkinsonian agents
CT Antipsychotics
CT Antitumor agents
CT Anxiety
CT Anxiolytics
CT Asthma
CT Brain, neoplasm
CT Cardiac arrhythmia
CT Cardiovascular agents
CT Cardiovascular system, disease
CT Cognition enhancers
CT Cognitive disorders
CT Convulsion
CT Coronary artery disease
CT Coronary spasm

CT Cystic fibrosis
CT Digestive tract, disease
CT Dysmenorrhea
CT Epilepsy
CT Gastrointestinal agents
CT Hearing loss
CT Human
CT Hypertension
CT Immunostimulants
CT Immunosuppression
CT Ischemia
CT Kidney, disease
CT Laxatives
CT Learning disorders
CT Myocardial ischemia
CT Narcolepsy
CT Neoplasm
CT Nervous system agents
CT Pain
CT Parkinson's disease
CT Prophylaxis
CT Seizures
CT Sjogren syndrome
CT Sleep apnea
CT Sleep disorders
CT Tocolytic agents
CT Urogenital system, disease
CT Mental and behavioral disorders
CT Nose, disease
CT Diarrhea
CT Blood vessel, disease
CT Nervous system, disease
CT Brain, disease
CT Brain, disease
CT Nerve, disease
CT Pain
CT Vision disorders
CT Mouth, disease
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L108 ANSWER 2 OF 2 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2002220093 EMBASE Full-text
TITLE: Gemcitabine plus cisplatin for the treatment of metastatic breast cancer.
AUTHOR: Heinemann V.
CORPORATE SOURCE: Dr. V. Heinemann, Medical Clinic III, Klinikum Grosshadern, Marchionini St 15, 81377 Munich, Germany. volker.heinemann@med3.uni-muenchen.de
SOURCE: Clinical Breast Cancer, (2002) Vol. 3, No. SUPPL. 1, pp. S24-S29. .
Refs: 30
ISSN: 1526-8209 CODEN: CBCLB7
COUNTRY: United States
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 016 Cancer
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 11 Jul 2002
Last Updated on STN: 11 Jul 2002

AB The combination of gemcitabine and cisplatin has proven effective as first-line chemotherapy for patients with breast cancer, inducing a response rate of 80% in one phase II study. Five additional studies in intensively pretreated breast cancer patients demonstrated a median response rate of 43% (range, 26%-50%). The toxicity profile was moderate, with thrombocytopenia and neutropenia as the main side effects. The gemcitabine/cisplatin combination, therefore, offers a tolerable and effective treatment option, particularly for patients whose disease progressed after treatment with anthracyclines and/or taxanes.

CT Medical Descriptors:
*breast cancer: DT, drug therapy
drug efficacy
cancer combination chemotherapy
drug response
thrombocytopenia: SI, side effect
neutropenia: SI, side effect
drug tolerability
cancer growth
cardiotoxicity: SI, side effect
dose response
antineoplastic activity
drug effect
nephrotoxicity: SI, side effect
peripheral neuropathy: SI, side effect
hearing loss: SI, side effect
drug resistance
neurotoxicity: SI, side effect
bone marrow toxicity: SI, side effect
metastasis potential
human
female
clinical trial
phase 2 clinical trial
controlled study
article
Drug Descriptors:
*gemcitabine: AE, adverse drug reaction
*gemcitabine: CT, clinical trial
*gemcitabine: CB, drug combination
*gemcitabine: CM, drug comparison
*gemcitabine: DO, drug dose
*gemcitabine: IT, drug interaction
*gemcitabine: DT, drug therapy
*gemcitabine: PD, pharmacology
*cisplatin: AE, adverse drug reaction
*cisplatin: CT, clinical trial
*cisplatin: CB, drug combination
*cisplatin: CM, drug comparison
*cisplatin: DO, drug dose
*cisplatin: IT, drug interaction
*cisplatin: DT, drug therapy
*cisplatin: PD, pharmacology
anthracycline derivative: AE, adverse drug reaction
anthracycline derivative: CB, drug combination
anthracycline derivative: DT, drug therapy
taxane derivative: DT, drug therapy

```
trastuzumab: CB, drug combination
trastuzumab: DT, drug therapy
trastuzumab: PD, pharmacology
  pyrimidine derivative: AE, adverse drug reaction
  pyrimidine derivative: CB, drug combination
  pyrimidine derivative: CM, drug comparison
  pyrimidine derivative: DO, drug dose
  pyrimidine derivative: IT, drug interaction
  pyrimidine derivative: DT, drug therapy
  pyrimidine derivative: PD, pharmacology
antineoplastic antimetabolite: AE, adverse drug reaction
antineoplastic antimetabolite: CB, drug combination
antineoplastic antimetabolite: CM, drug comparison
antineoplastic antimetabolite: DO, drug dose
antineoplastic antimetabolite: IT, drug interaction
antineoplastic antimetabolite: DT, drug therapy
antineoplastic antimetabolite: PD, pharmacology
docetaxel: CB, drug combination
docetaxel: DT, drug therapy
navelbine: CB, drug combination
navelbine: DT, drug therapy

=>
```